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Abstract 
The prospects of achieving regeneration in the Central Nervous System (CNS) have 
changed, as most recent findings indicate that several species, including humans, can 
produce neurons in adulthood. Studies targeting this property may be considered as 
potential therapeutic strategies to respond to injury or the effects of demyelinating 
diseases in the CNS. While CNS trauma may interrupt the axonal tracts that connect 
neurons with their targets, some neurons remain alive, as seen in optic nerve and 
spinal cord (SC) injuries (SCIs). The devastating consequences of SCIs are due to the 
immediate and significant disruption of the ascending and descending spinal pathways, 
which result in varying degrees of motor and sensory impairment. Recent therapeutic 
studies for SCI have focused on cell transplantation in animal models, using cells 
capable of inducing axon regeneration like Schwann cells (SchCs), astrocytes, 
genetically modified fibroblasts and olfactory ensheathing glia cells (OECs). 
Nevertheless, and despite the improvements in such cell-based therapeutic strategies, 
there is still little information regarding the mechanisms underlying the success of 
transplantation and regarding any secondary effects. Therefore, further studies are 
needed to clarify these issues. In this review, we highlight the properties of OECs that 
make them suitable to achieve neuroplasticity/neuroregeneration in SCI. OECs can 
interact with the glial scar, stimulate angiogenesis, axon outgrowth and remyelination, 
improving functional outcomes following lesion. Furthermore, we present evidence of 
the utility of cell therapy with OECs to treat SCI, both from animal models and clinical 
studies performed on SCI patients, providing promising results for future treatments. 
 
Keywords: Olfactory ensheathing glia cells, Cell therapies, Transplantation, Spinal cord 
injuries, Cell transplantation, Neuroregeneration. 
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1  І  INTRODUCTION 
Spinal cord injury (SCI) is a secondary outcome of a compression injury, bleeding 
and/or ischemia, which compromises the bone component of the spine, the spinal 
cord (SC) and its coverings. Several mechanisms can cause this type of damage, the 
most common bone injury being bone disruption produced by flexo-extension injuries 
associated with fracture (Ahuja, Martin, & Fehlings, 2016; McDonald and Sadowsky, 
2002; Rogers and Todd, 2016). The pathological features of traumatic SCI include axon 
demyelination, which is in part due to the loss of the glial substrate at the site of injury 
as a combined result of necrosis, apoptosis and autophagy (McDonald and Sadowsky, 
2002; Plemel et al., 2014). In the days and weeks following SCI there is extensive 
oligodendrocyte loss and widespread demyelination, which can already be detected at 
7 days post injury (DPI) (Plemel et al., 2014). 
SCI generates a series of temporary anatomical and pathological changes. After the 
first pathological events associated with injury (see below), a secondary phase begins 
from 1 to 3 DPI, and a loss of blood vessels, neurons, glial cells and axonal tracts occurs 
in this phase. These events are responsible for the loss of function in most nervous 
system injuries (Botero, Gómez, & Chaparro, 2013; McDonald and Sadowsky, 2002). As 
such, SCI can generally be divided into different clinical phases: 
i) Acute SCI - with destruction of the blood-brain barrier, alterations to the 
microvasculature of the grey matter and induction of petechial haemorrhages, 
which has also been linked with the formation of oedema, thrombin production 
and erythrocyte lysis. Vascular changes and haemorrhages fulfil a crucial role in the 
initial pathological events leading to neuronal cell death and axonal damage 
(Gerzanich et al., 2009; Griffiths, Burns, & Crawford, 1978; Losey and Anthony, 
2014; Losey, Young, Krimholtz, Bordet, & Anthony, 2014; Yu and Fehlings, 2011). 
The presence of inflammatory cells can also be observed, especially that of 
neutrophils, which have been detected as soon as three minutes after a contusion 
injury and that are related to the extent of injury (Griffiths et al., 1978; Taoka et al., 
1997; Yu and Fehlings, 2011). In addition to the vascular changes, several 
pathophysiological events take place after SCI. There is a loss of ionic regulation 
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that leads to a loss of nerve impulses and oedema formation. An increase of free 
intracellular calcium also occurs, which activates the proteases and phospholipases 
that are involved in the destruction of myelin (Balentine, 1988). Glutamate and 
aspartate release also produces the excessive excitation of viable neurons and 
there is a disruption of redox homeostasis, with the consequent generation of free 
radicals (e.g., superoxide anions, hydrogen peroxide, hydroxyl anions, etc.: (Tator 
and Fehlings, 1991). 
ii) Subacute SCI - in which glial cell activation occurs as a result of necrosis, 
haemorrhage and local ischemia, and in which neuronal and oligodendroglial 
apoptosis takes place (Spitzbarth et al., 2011; Tator and Koyanagi, 1997; Yu and 
Fehlings, 2011). 
iii) Chronic SCI - in which the degenerative process continues and extends beyond the 
primary lesion (Gomez, 2009; McDonald and Sadowsky, 2002; Tator and Koyanagi, 
1997). 
Glial and neuronal degeneration, and demyelination is evident in each of these phases, 
with morphological and structural abnormalities in both the grey and white matter 
associated with complete SCI (Botero, 2015; McDonald and Sadowsky, 2002). 
After SCI, severe functional deficits generally appear as a result of the disconnection in 
the spinal tract, a condition that persists due to the poor capacity for spontaneous 
axonal regeneration of the neurons implicated. This is due to several problems: i) 
intrinsic neuronal deficits in the expression of genes implicated in axon 
regrowth/regeneration (Bomze, Bulsara, Iskandar, Caroni, & Skene, 2001; Hannila and 
Filbin, 2008); ii) the presence of inhibitory factors in the glial scar that develops after 
trauma (Cregg et al., 2014; Silver and Miller, 2004; Yiu and He, 2006); and iii) a lack of 
trophic factors for neuroprotection and regeneration (Jones, Oudega, Bunge, & 
Tuszynski, 2001; Sharma, 2007). 
Functional recovery from the SCI depends on its pathophysiology (Tator, 1998) and 
different therapeutic strategies have been considered to achieve this, both individually 
and in combination. These strategies include approaches that involve the provision of 
neurotrophic factors, overcoming glial scar inhibitory factors and cell transplantation 
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(Assinck, Duncan, Hilton, Plemel, & Tetzlaff, 2017; Bunge, 2008; Jones et al., 2001; 
Moreno-Flores and Avila, 2006; Moreno-Flores and Avila, 2010). Glial cell 
transplantation aims to provide neuroprotection and/or promote the 
plasticity/myelination of spared fibres, and/or to foster axon regeneration. Stem cell 
transplantation aims to provide new glial cells for myelination or neuroprotection, or 
new neurons to replace the lost ones and/or to provide synaptic relays (Erceg et al., 
2010; Lu et al., 2012; Moreno-Flores and Avila, 2006; Moreno-Flores and Avila, 2010; 
Moreno-Manzano et al., 2009; Okano, 2002; Zurita and Vaquero, 2006; Zurita et al., 
2008). In animal SCI models of diverse severity, promising results have been obtained 
by transplanting different cell types, such as: 
- Schwann cells (SchCs) or peripheral nerve grafts (Cheng, Cao, & Olson, 1996; 
Kanno, Pearse, Ozawa, Itoi, & Bunge, 2015); 
- Olfactory ensheathing glia cells (OECs: (Li, Field, & Raisman, 1997; Lopez-Vales, 
Fores, Verdu, & Navarro, 2006; Lu, Feron, Ho, Mackay-Sim, & Waite, 2001; Ramon-
Cueto and Nieto-Sampedro, 1994; Ramon-Cueto, Plant, Avila, & Bunge, 1998; 
Ramon-Cueto, Cordero, Santos-Benito, & Avila, 2000); 
- Genetically modified OECs (Lim et al., 2010; Moreno-Flores et al., 2006); 
- Olfactory mucosa (OM) grafts (Iwatsuki et al., 2008); 
- Different types of stem cells (Assinck et al., 2017; Deshpande et al., 2006; Erceg et 
al., 2010; Lu et al., 2012; Okano, 2002), including ependymal stem cells (Moreno-
Manzano et al., 2009), bone marrow mesenchymal stem cells (Laroni, Novi, 
Kerlero, & Uccelli, 2013; Novikova, Brohlin, Kingham, Novikov, & Wiberg, 2011; 
Urdzikova et al., 2006; Zurita and Vaquero, 2006; Zurita et al., 2008) and 
mesenchymal stem cells (MSCs) from the human mucosa lamina propria (OM-
MSCs: (Lindsay, Riddell, & Barnett, 2010; Lindsay and Barnett, 2017; Lindsay et al., 
2017). 
- Fibroblasts and genetically modified fibroblasts (GMFs: (Franzen, Martin, Daloze, 
Moonen, & Schoenen, 1999; Grill, Murai, Blesch, Gage, & Tuszynski, 1997; Grill, 
Blesch, & Tuszynski, 1997; Tuszynski, Murai, Blesch, Grill, & Miller, 1997). 
This review focuses on OECs due to their inherent ability to support the continuous 
renewal of olfactory neurons in the olfactory system, and their ability to stimulate 
axon repair/plasticity/sparing and functional recovery in the central nervous system 
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(CNS: (Barnett and Riddell, 2007; Franssen, de Bree, & Verhaagen, 2007; Moreno-
Flores, Diaz-Nido, Wandosell, & Avila, 2002; Ramon-Cueto and Valverde, 1995). 
 
2  І  ONTOGENY OF OLFACTORY ENSHEATHING GLIA CELLS 
(OECs) 
OECs are a type of macroglia located in the OM lamina propria (LP) of the peripheral 
nervous system (PNS) and in the CNS, in the external layer of the olfactory bulb (OB), 
the olfactory nerve layer (ONL). These cells are organized along the pathway from the 
OM to the OB and they are derived from the embryonic ectoderm in the olfactory 
placodes at the lateral-face of the embryo’s head. It is from this region that the 
migratory mass that gives rise to the olfactory nerve originates. Finally, the cells and 
bundles of axons of this mass reach the prospective OB in the telencephalic vesicle, 
which originates from the mantle of the forebrain (Chuah and Au, 1991; Doucette, 
1990; Doucette, 1993; Miller, Treloar, & Greer, 2010; Ramon-Cueto and Valverde, 
1995; Valverde, Santacana, & Heredia, 1992). 
Recent studies established a dual source of OECs, implicating the neural crest in their 
origin together with the ectodermal placodes (Katoh et al., 2011). Indeed, more recent 
studies using fate-mapping techniques and genetic lineage tracing suggest that OECs 
are exclusively derived from the neural crest (Fig. 1: (Barraud et al., 2010; Forni, Taylor-
Burds, Melvin, Williams, & Wray, 2011). These neural crest cells would later contribute 
to the ectodermal derived cranial placodes (Forni et al., 2011) and therefore, OECs 
share a common developmental lineage with SchCs. This modifies the previous model 
of OEC development and it could explain the similarities between both types of cells 
(Barraud et al., 2010; Forni et al., 2011). Moreover, because stem cells from the neural 
crest persist in adult tissue, these cells could provide an accessible source of OECs for 
autologous SCI therapy (Barraud et al., 2010). 
The normal physiology of OECs in the adult is not yet well understood. In the mature 
olfactory neuroepithelium (Fig. 2), sensory neurons renew with a turnover of around 
28 days (Chuah and West, 2002). New olfactory neurons extend an apical dendrite and 
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a basal axon, and these new axons fasciculate with other ones to grow in the right 
direction through the LP (connective tissue), cross the cribriform plate of the ethmoids, 
and finally reach the OB in the CNS to connect with their targets in the glomeruli 
(Chuah and West, 2002). Two types of neural stem cells coexist in the adult olfactory 
epithelium, the globose basal cells (GBCs) and the horizontal basal cells (HBCs, see 
Fig.2; (Carr, Farbman, Colletti, & Morgan, 1991; Frisch, 1967; Graziadei and Graziadei, 
1979; Holbrook, Szumowski, & Schwob, 1995). The former are the main source of 
neurons that give rise to the main cell populations of the mucosa, whereas the second 
cell type (HBCs) are normally inactive, although they can be activated to generate new 
GBCs and reconstitute the population of the olfactory epithelium after extreme injury 
(Carter, MacDonald, & Roskams, 2004; Leung, Coulombe, & Reed, 2007). However, the 
true origin of new OECs in vivo has not yet been fully clarified and thus, it is still not 
clear how the turnover of OECs in the adult mucosa takes place. Some in vitro studies 
suggest that HBCs could give rise to new OECs, perhaps through intermediate steps 
involving precursor cells (Carter et al., 2004). Nevertheless this process might be very 
slow or rare in vivo. In this sense, it was shown that OECs do not divide or noticeably 
migrate within the olfactory system in response to a lesion of the OM (zinc sulphate 
irrigation). These studies suggest that regenerating olfactory nerve processes grow 
through conduits of remaining OECs, implying that these cells and their conduits 
persist as “pathways” for regenerating fibres (Williams, Franklin, & Barnett, 2004). 
 
3  І  OLFACTORY CELL CHARACTERISTICS AND THEIR ORIGINS 
IN THE OM OR OB 
OECs are elongated in shape with a thin laminar process that wraps around the 
olfactory nerves in situ, while they are characterized by their flat, bipolar or multipolar 
morphology in culture (Franceschini and Barnett, 1996; Vincent, West, & Chuah, 2005). 
OECs are present in both the peripheral olfactory nerve and in the ONL of the OB in the 
CNS (Vincent et al., 2005). They express several recognized markers (Figs. 3A and B) 
that can be detected by immunostaining in vitro and in vivo (Alexander, Fitzgerald, & 
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Barnett, 2002; Franceschini and Barnett, 1996; Gomez et al., 2016; Vincent et al., 
2005). However, the expression of these proteins depends on their state of 
differentiation and their location in the CNS or PNS (Vincent et al., 2005). In the adult 
OB in vivo (Fig. 3A), OECs express S100β, an intracellular calcium binding protein, and 
the intermediate filament protein GFAP (glial fibrillary acidic protein), albeit more 
weakly. In addition, OECs located in the outer area of the ONL of the OB weakly 
express the low-affinity NGF receptor, p75NTR, and the embryonic form of the neural 
cell adhesion molecule, E-NCAM. By contrast, in the inner area of the ONL these cells 
express neuropeptide Y (NPY) but not p75NTR or E-NCAM (Barnett, Hutchins, & Noble, 
1993; Franceschini and Barnett, 1996; Ubink, Halasz, Zhang, Dagerlind, & Hokfelt, 
1994; Valverde et al., 1992; Vincent et al., 2005). In the adult mouse, cells containing 
S100 are distributed throughout the ONL, and p75NTR also appears to be restricted to 
the olfactory nerve and the outer ONL. While NPY positive OEC processes are located 
in the inner ONL, GFAP positive processes appear to be distributed in the inner ONL, at 
the ONL/glomerular layer boundary and in the glomerular layer, defining loosely 
aggregated axon fascicles that enter the glomeruli obliquely (Au, Treloar, & Greer, 
2002). However, a population of unidentified glial cells positive for GFAP but not S100 
has also been detected (Au et al., 2002). 
During the in vitro characterization of the OECs obtained from cultures of the neonatal 
rat OB, subpopulations of cells have been found with morphological and proteomic 
features similar to those described above (Fig. 3B). These subpopulations were defined 
as: i) astrocyte-like, similar in morphology to flattened astrocytes, and characterized by 
the expression of E-NCAM and GFAP (fibrous appearance); and ii) SchC-like, spindle 
shaped, similar in morphology to SchCs, and characterized by the expression of 
p75NTR, weak (diffuse) GFAP expression and a lack of E-NCAM (Franceschini and 
Barnett, 1996). 
Although these studies described the existence of these two populations of OECs in 
vitro and in vivo (Franceschini and Barnett, 1996; Pixley, 1992), it is not possible to 
accurately determine if these two populations exist in the ONL of the OB, as variations 
in protein expression at different stages of development cannot be ruled out. In 
addition, the acquisition of different morphologies and markers by clonal OECs in 
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response to the culture conditions must be considered (Alexander et al., 2002; 
Franceschini and Barnett, 1996; Moreno-Flores et al., 2003a; Moreno-Flores et al., 
2003b; Moreno-Flores et al., 2006; Pixley, 1992; Vincent et al., 2005). Furthermore, 
OECs are migratory cells (Huang et al., 2008; Nocentini et al., 2012; Reginensi et al., 
2015; Windus, Claxton, Allen, Key, & St John, 2007) and dynamic lamellipodal waves 
are crucial for cell migration (Windus et al., 2007). Through the re-organization of the 
cytoskeleton, different phenotypes with flattened and spindle-shaped morphologies 
can be generated (the morphological characteristics of astrocytes and SchCs, 
respectively), producing unique OEC subpopulations that can spontaneously transform 
from one to the other (Huang et al., 2008). 
Finally, other potential phenotypic OEC markers have been described, such as 
Calponin, an actin binding protein associated with smooth muscle contraction and 
smooth muscle α-actin, and a marker that can help differentiate OECs from SchCs in 
vitro and in vivo (Boyd et al., 2006; Jahed et al., 2007; Rizek and Kawaja, 2006). 
However, conflicting results have been obtained when trying to test these markers 
(Ibanez, Ito, Zawadzka, Jeffery, & Franklin, 2007), and calponin expression defined 
subpopulations of mucosal connective tissue cells rather than OECs in embryonic and 
neonatal tissue. In vitro punctate staining appears to be non-specific, seen also in 
astrocytes and fibroblasts (Tome, Siladzic, Santos-Silva, & Barnett, 2007), and 
therefore, calponin seem not be a specific OEC marker. 
A growing number of studies have been performed to obtain OECs in vitro from 
different sources of tissue: from the OB or OM of neonatal, early post-natal and young 
rodents (Au and Roskams, 2002; Au and Roskams, 2003; Barnett et al., 1993; Gomez et 
al., 2016; Pixley, 1992); from adult rodents (Jani and Raisman, 2004; Ramon-Cueto and 
Nieto-Sampedro, 1992); or from young and adult humans (Garcia-Escudero et al., 
2010; Garcia-Escudero et al., 2012; Jani and Raisman, 2004; Lim et al., 2010). It has not 
been possible to extract accurate generalizations from these studies due to the 
difficulty in comparing results from such a variety of sources, and given the different 
culture techniques that have been employed and the distinct antigenic features have 
been used to define OECs in each. Moreover, while OB and OM derived cells have been 
evaluated in vitro and in vivo, there is still no consensus regarding the “adequate” 
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regenerative histological features or on the use of OECs derived from different sources. 
Nevertheless, the culture method (Garcia-Escudero et al., 2012) and composition of 
these cultures seems to be fundamental to the nature of the cells obtained (Ibrahim et 
al., 2014; Jani and Raisman, 2004; Mayeur et al., 2013). It was proposed that OM and 
OB derived OECs both have the same potential, both reducing astrocyte reactivity and 
hindering the formation glial scar, as well as promoting axonal regrowth, and 
electrophysiological and functional recovery (Mayeur et al., 2013). Moreover, it was 
concluded that the accessibility of OM-OECs gave them the best benefit/risk ratio. OM 
and OB OECs were also compared in a rat transplantation model of SCI and although 
they exhibit some distinct properties (see below “OEG transplantation in animal 
models of SCI“), both reduced the size of the lesion and of the cavity in the SC, and 
provoked differential sprouting of spinal axon tracts (Richter, Fletcher, Liu, Tetzlaff, & 
Roskams, 2005). Despite the possible biological differences between these types of 
OECs, both have neuroregenerative properties, fostering axon outgrowth from adult 
CNS neurons in culture (Garcia-Escudero et al., 2012). Nevertheless, it should be noted 
that cultures from a dissected OM can contain a small proportion of p75NTR-positive 
cells, which could explain the lack of an effect of the OM cells when transplanted in a 
rat model of rhizotomy, as opposed to that of cells cultured from the OB. OM cells 
failed to produce axonal regrowth across the severed roots and functional restoration 
(forepaw grafting: (Ibrahim et al., 2014; Li, Carlstedt, Berthold, & Raisman, 2004). 
However, the results of clinical studies (Tabakow et al., 2013; Tabakow et al., 2014) 
should also be considered in this regard (see below “OECs to cure SCI: Clinical 
studies”). In our hands, immortalized rat OEC clonal cell lines originating from the OB 
develop different morphologies in culture depending on the composition of the culture 
medium. Additionally, many cells lose their p75NTR expression without losing their 
capacity to promote axon regeneration in co-culture with CNS neurons (Moreno-Flores 
et al., 2003a; Moreno-Flores et al., 2003b). Indeed, these immortalized clonal cells 
favour in vivo axonal repair/sprouting/sparing and functional recovery (Moreno-Flores 
et al., 2006). Nevertheless, the data available do indicate that the cells obtained from 
the OM are a mixture of cell populations. 
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Such variety in the stem cells and OECs in the OM was also proposed following clinical 
studies of OM grafts transplanted into regions of SCI (Lima et al., 2006), and the OM 
has recently been confirmed as a potential source of adult stem cells (Feron, Perry, 
Girard, & Mackay-Sim, 2013; Girard et al., 2011; Lindsay et al., 2013; Lindsay, 
Johnstone, McGrath, Mallinson, & Barnett, 2016; Lindsay and Barnett, 2017; Nivet et 
al., 2011; Stamegna et al., 2014; Tome, Lindsay, Riddell, & Barnett, 2009). In addition 
to OECs, human OM biopsies contain up to 5% mesenchymal-like stromal cells from 
the LP. Using miRNA-based fingerprinting these cells were shown to be 64% 
homologous to bone marrow-derived MSCs (BM-MSCs: (Lindsay et al., 2016), although 
they also had other specific properties. OM-MSCs differed from classical BM-MSCs 
through their anti-inflammatory properties, secreting less pro-inflammatory cytokines, 
and their stronger capacity to promote rat oligodendrocyte myelination in vitro 
(Lindsay et al., 2016). These cells maintain the properties of all MSCs in general and the 
specific properties of OM-MSCs in particular. Therefore, they may be a good 
alternative for transplantation after SCI or CNS lesions (Assinck et al., 2017; Laroni et 
al., 2013).  
 
4  І  MOLECULAR FEATURES AND CELLULAR FUNCTIONS OF 
OECs  
The adult olfactory system is composed of the OM, which contains the peripheral 
sensory neurons whose axons form the olfactory nerve, and the OB that is part of the 
CNS. During the lifetime of a mammal, olfactory sensory neurons die regularly as a 
result of environmental exposure and they are replaced by newly differentiated 
neurons. These new neurons grow axons that enter the OB and establish new synapses 
with their targets (Costanzo, 1985; Doucette, Kiernan, & Flumerfelt, 1983; Farbman, 
1994; Graziadei and Graziadei, 1979; Harding, Graziadei, Monti Graziadei, & Margolis, 
1977). This remarkable capacity of the olfactory system is due to the special properties 
of the glia cells on which this review focuses, OECs (Doucette, 1984; Doucette, 1990; 
Doucette, 1991; Raisman, 1985). In addition, precursors in the stem niche of the 
olfactory system and the characteristics of OECs enable functional neural connections 
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with targets in the CNS to be re-established after injury (e.g. transection of the 
olfactory nerve: (Doucette, 1984; Doucette et al., 1983; Doucette, 1995; Harding et al., 
1977). 
OECs perform specific functions within the olfactory system. In the OM they provide a 
favourable environment for the development of sensory axons, which fasciculate to 
form the first cranial nerve, and that grow through these territories to enter the CNS 
and establish functional synapses in the OB glomeruli. OECs ensheath, accompany and 
guide these axons from the OM to the OB (Doucette, 1990; Doucette, 1995; Moreno-
Flores et al., 2002; Ramon-Cueto and Valverde, 1995). OECs and olfactory axons 
maintain communication by evoking calcium signals via glutamatergic and purinergic 
pathways (Rieger, Deitmer, & Lohr, 2007), and these axons do not establish synapses 
until they arrive at the glomeruli in the OB. The cytoplasmic prolongations of OECs 
envelop these packages of axons, acting as an insulator and ensuring they avoid 
coming into contact with other inhibitory CNS factors that would otherwise restrict 
axonal growth. 
The molecular mechanism by which OECs support axonal outgrowth are yet not fully 
understood, although several of the molecules responsible for this capacity have been 
identified in recent years. OECs are known to express a number of proteins that can aid 
such events, including membrane bound and secreted adhesion molecules that 
promote axonal growth (Table 1A & Fig. 4): L1, E-NCAM, laminin, fibronectin, type IV 
collagen, and amyloid precursor protein (APP)(Doucette, 1996; Franceschini and 
Barnett, 1996; Kafitz and Greer, 1998; Moreno-Flores et al., 2003a). These molecules 
can act as favourable substrates for axonal growth, and laminin in particular is a 
preferential substrate for in vitro neurite extension by olfactory neurons (Kafitz and 
Greer, 1997).  
OECs are also characterized by the secretion of diffusible factors - neurotrophins (NTs) 
and other trophic factors responsible for neurite extension by olfactory neurons in 
vitro (Kafitz and Greer, 1999). NTs fulfil an important role in neuronal development, 
promoting proliferation, survival or axonal outgrowth (Huang and Reichardt, 2001; 
Huang and Reichardt, 2003) through their specific tyrosine kinase receptors, Trks, 
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which in turn activate intracellular signaling through G proteins like Ras, Rap-1 and 
Cdc-42 (Huang and Reichardt, 2001; Huang and Reichardt, 2003). Cultured OECs 
express mRNA for nerve growth factor (NGF), brain derived neurotrophic factor 
(BDNF), glial cell-derived neurotrophic factor (GDNF), neurturin (NTN) and neuregulins 
(Boruch et al., 2001; Lipson, Widenfalk, Lindqvist, Ebendal, & Olson, 2003; Moreno-
Flores et al., 2002; Pastrana et al., 2007; Woodhall, West, & Chuah, 2001), as well as 
their receptors TrkB, TrkC, GFRα-1 and GFRα-2 (Table 1A & Fig. 4: (Lipson et al., 2003; 
Woodhall et al., 2001). In addition, the intracellular presence and the secretion of NGF, 
BDNF (Pastrana et al., 2007; Woodhall et al., 2001) and neuregulin (Boruch et al., 2001) 
has been confirmed by immunocytochemistry and ELISA (Table 2). While some 
contradictory results have been obtained regarding NT-4 and ciliary neurotrophic 
factor (CNTF) mRNA expression ((Boruch et al., 2001; Lipson et al., 2003), some of 
these studies were carried out on a clonal OEC line. Moreover, mRNA for S100β, CNTF, 
BMP7/OP-1 and artemin has been detected in the ONL of the OB, as has that encoding 
the RET and TrkC receptors in the ONL (Lipson et al., 2003). 
Considering their patterns of expression, it seems that some of these trophic factors 
may exert an autocrine effect on OECs, e.g. the ligand/receptor pairs NGF/p75NTR, 
BDNF/TrkB, GDNF/GFRα-1 and NTN/GFRα-2. In the case of GDNF and NTN, conflicting 
results have been reported regarding the expression of the transducing subunit of 
these receptors, RET. RET mRNA was not detected in cultured OECs, suggesting that 
these cells lack RET and thus, as they would be unable to transduce the signals from 
GDNF and NTN, and that they might simply bind and present these factors to growing 
neurons (Woodhall et al., 2001). However, the subunits of these receptors and RET 
mRNA were detected in the ONL of the OB (Lipson et al., 2003), where OECs constitute 
the main type of cell. Thus, the function of GDNF and NTN in the olfactory system still 
remains uncertain. 
Specific neuregulins, such as NRG-1 isoforms, are trophic factors for OECs, acting 
through ErbB receptors (Moreno-Flores et al., 2002) given that  OECs express ErbB2, 3 
and 4 in culture (Table 1A: (Moreno-Flores et al., 2003b; Pollock, Franceschini, Graham, 
Marchionni, & Barnett, 1999). Therefore, neuregulins may also exert autocrine effects 
on these cells. OECs also express other molecules that have neurotrophic effects, like 
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S100β (Franceschini and Barnett, 1996; Lipson et al., 2003; Vincent et al., 2005), and 
that may fulfil important functions in brain development (Barger, Wolchok, & Van 
Eldik, 1992; Marshak, 1990; Modi and Kanungo, 2010). Similarly, they produce 
cytokines that can play a relevant role in neuroprotection and repair (Table 1A & Fig. 
4), including interleukin-6, CX3CL1/Fractalkine (Nan, Getchell, Partin, & Getchell, 2001; 
Roet and Verhaagen, 2014; Ruitenberg et al., 2008), and transforming growth factor β3 
(TGFβ3) (Pastrana et al., 2006). OECs also express cytokines receptors, like tumour 
necrosis factor receptors (TNFR) (Roet and Verhaagen, 2014), interleukin-1 receptor 
like-1 (IL1RL1) (Pastrana et al., 2006) and after bulbectomy, interleukin-6 receptor (IL-
6R) and Leukemia inhibitory factor receptor (LIFR) (Nan et al., 2001). Importantly, OECs 
secrete proteases that promote axonal regeneration, such as MMP2 (matrix 
metalloprotease 2), MMP9 and serpine-1 (Tables 1A, 2 & Fig. 4: (Pastrana et al., 2006; 
Simon et al., 2011).  
Some subtypes of OECs express specific molecules, and a subpopulation of OECs with 
low p75NTR has been shown to overexpress genes that regulate the inflammatory 
response and axon guidance, such as the EphB2 receptor (Honore et al., 2012). Also, a 
high p75NTR subpopulation overexpresses molecules that modulate the extracellular 
matrix, neurite outgrowth and axonal fasciculation/defasciculation, including Laminin, 
collagen type V, alpha 1 and alpha2, and collagen type I, alpha 1  (Honore et al., 2012). 
Moreover, LP-OECs express type V, alpha 4 collagen and a specific combination of 
proteins important for development, including CD44, integrin-β1, Notch 3, VEGF 
(Vascular Endothelial Growth Factor), and the chondroitin sulphate proteoglycan 4, 
NG2 (Au and Roskams, 2003). 
OECs not only express factors that promote neuroregeneration but they also express 
some inhibitory factors (Table 1B & Fig. 4), although the significance of this is not yet 
well understood. OECs express Nogo and their NgR receptor (Nocentini et al., 2012; Su 
et al., 2007; Woodhall, West, Vickers, & Chuah, 2003), and the latter has a direct effect 
on the capacity of OECs to migrate on myelin or myelin-derived substrates in vitro 
(Nocentini et al., 2012; Reginensi et al., 2015). Significantly, this phenomenon may 
affect their ability to penetrate the glial scar. Several molecules have been seen to 
regulate OEC migration, either positively, like GDNF (Cao et al., 2006), or negatively like 
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Myelin, NogoA, chondroitin sulphate proteoglycans (CSPGs (Nocentini et al., 2012; 
Reginensi et al., 2015; Su et al., 2007), the axonal guidance molecule Slit-2, ligand of 
Robo receptors (Huang et al., 2011; Wang and Huang, 2012), and fibulin-3 (Vukovic et 
al., 2009b). Furthermore, OECs express other inhibitory molecules (Table 1B & Fig. 4) 
like Ephrin A1 in long passaged and immortalized OECs (Pastrana et al., 2006) and 
secreted semaphorins (e.g., Sema3A: Table 2), although this is required for olfactory 
axon guidance and patterning of the OB (Schwarting et al., 2000). As indicated above, a 
low p75NTR OEC subpopulation overexpresses the EphB2 receptor (Honore et al., 
2012) that mediates axon repulsion (Klein, 2012; Orioli and Klein, 1997), and LP-OECs 
express the CSPG 4, NG2 (Au and Roskams, 2003). The inhibitory influence of NG2 on 
axon growth is still highly controversial because it has been associated with both 
inhibitory effects (Fidler et al., 1999; Tan, Colletti, Rorai, Skene, & Levine, 2006; Ughrin, 
Chen, & Levine, 2003) and the permissiveness of NG2 expressing cells (Busch et al., 
2010; Vadivelu et al., 2015; Yang et al., 2006). At present, new exciting findings are still 
emerging in this field (see (Nishihara et al., 2015) and it appears that the expression of 
NG2 by some cells it is not necessarily correlated with the inhibition of axon 
regeneration. In fact, the effects of NG2 may depend on the expression of other 
molecules, such as MMP9 (Vadivelu et al., 2015) or MMP14 (Nishihara et al., 2015). 
 
5  І  OECs IN SPINAL CORD INJURY (SCI) REPAIR 
5.1 І  CNS Regeneration: a brief overview 
From Cajal’s historic studies, it was clear that unlike PNS neurons, adult CNS neurons 
do not regenerate (Ramon y Cajal, 1928). In pioneering studies, this was shown not to 
be due to an intrinsic or irreversible incapacity of the CNS neurons (Bray, Villegas-
Perez, Vidal-Sanz, & Aguayo, 1987; Vidal-Sanz, Bray, Villegas-Perez, Thanos, & Aguayo, 
1987), findings that stimulated the use of peripheral nerve and SchC grafts to foster 
regeneration in the CNS, with promising results (reviewed in (Jones et al., 2001; 
Oudega and Xu, 2006). 
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Intrinsic restrictions that prevent adult CNS neurons from expressing the genes 
necessary to re-initiate their “developmental” program after injury has been 
demonstrated, and these may be overcome. Dorsal root ganglia (DRG) sensory neurons 
regenerate the central branch and dorsal column sensory projections after injury, yet 
only after a conditioning lesion of the peripheral axonal branches of these neurons 
(injuring the sciatic nerve for example). Under these conditions, CNS axons of DRG 
neurons regenerate and this is accompanied by an important increase in the levels of 
DRG-cAMP (Bomze et al., 2001; Neumann, Bradke, Tessier-Lavigne, & Basbaum, 2002; 
Qiu et al., 2002). As a result, these neurons are no longer inhibited by myelin 
associated glycoprotein (MAG), an effect that is PKA dependent (Qiu et al., 2002). 
Direct intraganglionic injection of cAMP analogues (di-butyryl-cAMP) enables DRG 
neurons to grow on an inhibitory substrate (in culture) and to regenerate dorsal 
column sensory projections after lesion in vivo (Neumann et al., 2002; Qiu et al., 2002). 
In an elegant study, central sensory projections of DRG neurons were shown to 
regenerate in transgenic mice co-expressing the growth cone proteins GAP43 and 
CAP23, without the induction of a conditioning lesion (Bomze et al., 2001). Indeed, the 
regeneration of central sensory projections dependent on peripheral lesion takes place 
in conjunction with an increase in the expression of GAP43 by DRG neurons. Moreover, 
this regeneration is dependent on STAT3 activation and on the presence of interleukin-
6, although not in all cases (Cafferty et al., 2004; Hannila and Filbin, 2008; Qiu, 
Cafferty, McMahon, & Thompson, 2005). Thus, GAP43 and/or CAP23, or other 
alternative proteins needed for axon growth (but no longer expressed in the adult 
CNS), may be necessary for the regeneration of some injured neurons (Moreno-Flores 
and Avila, 2010). 
There is a wealth of experimental evidence that the microenvironment of CNS injury is 
fundamental in the inhibition of axon outgrowth and regeneration. Adult CNS neurons 
are normally surrounded by an organized extracellular matrix (ECM), referred to as the 
perineuronal net (PNN: Fig. 4), which can be visualized by immunostaining or by lectin 
labelling (e.g. with Wisteria floribunda agglutinin: (Miyata, Nishimura, Hayashi, & 
Oohira, 2005). Some CSPGs, hyalectans of the aggrecan family, are anchored to the 
PNN by Hyaluronan (HA), and this binding is stabilized by small proteins called link 
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proteins (Hardingham, 1979). HA is considered central to the structure of the CNS ECM 
and the PNN is known to be rich in CSPGs that inhibit neurite outgrowth (Celio, 
Spreafico, De Biasi, & Vitellaro-Zuccarello, 1998; Crespo, Asher, Lin, Rhodes, & Fawcett, 
2007; Rhodes and Fawcett, 2004). Thus, in normal physiological conditions in which 
they do not need to regrow their dendrites or axons, adult neurons are surrounded by 
these stable “cages”. After CNS lesion, the neuron-glia architecture is completely 
modified, provoking molecular changes and affecting the interactions between neural 
cells. Some neurons die as a direct consequence of the lesion and others die later, in a 
secondary process driven by neurotransmitter excitotoxicity and inflammatory 
responses. Soon after lesion, a glial reaction occurs giving way to the formation of a 
“glial scar” to re-establish the CNS glial boundary (glia limitans). This glial scar contains 
many elements and it is the main source of molecules that inhibit axon regeneration 
(Bovolenta, Wandosell, & Nieto-Sampedro, 1992; Bovolenta, Wandosell, & Nieto-
Sampedro, 1993a; Bovolenta, Fernaud-Espinosa, Mendez-Otero, & Nieto-Sampedro, 
1997; David and Lacroix, 2003; Sandvig, Berry, Barrett, Butt, & Logan, 2004; Silver and 
Miller, 2004). 
Following CNS lesion, astrocytes become hypertrophic and they express molecules that 
strongly inhibit axonal regrowth (e.g. CSPGs: (Bovolenta et al., 1997; Carri, Perris, 
Johansson, & Ebendal, 1988; Davies, Goucher, Doller, & Silver, 1999; Dou and Levine, 
1994; Fidler et al., 1999; McKeon, Schreiber, Rudge, & Silver, 1991; McKeon, Hoke, & 
Silver, 1995; Muir, Engvall, Varon, & Manthorpe, 1989; Niederost, Zimmermann, 
Schwab, & Bandtlow, 1999; Smith-Thomas et al., 1994). Several CSPGs from reactive 
astrocytes are upregulated after CNS injury, including aggrecan (CSPG1), versican 
(CSPG2), neurocan (CSPG3) and phosphacan (Asher et al., 2000; Fawcett and Asher, 
1999; Levine, 1994; McKeon, Jurynec, & Buck, 1999; Plant, Bates, & Bunge, 2001; Yiu 
and He, 2006). By eliminating CSPG glycosaminoglycan (GAG) chains, CSPG inhibitory 
activity is attenuated (Bovolenta et al., 1993a; Fidler et al., 1999; McKeon et al., 1995; 
Moon, Asher, Rhodes, & Fawcett, 2001; Zuo, Neubauer, Dyess, Ferguson, & Muir, 
1998) and see (Moreno-Flores and Avila, 2010) for review). In terms of their receptors, 
the common leukocyte antigen-related phosphatase (LAR), protein tyrosine 
phosphatase σ (PTPσ), NgR and NgR3 have recently been identified as receptors for the 
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inhibitory glycosylated side chains of CSPGs (Dickendesher et al., 2012; Fisher et al., 
2011; Shen et al., 2009). Moreover, microglia cells proliferate and also become reactive 
(Bovolenta, Wandosell, & Nieto-Sampedro, 1993b; Fernaud-Espinosa, Nieto-Sampedro, 
& Bovolenta, 1993). 
The neuronal bodies that contribute to the damaged axonal tracts in the SC lie at a 
distance from the site of injury. Hence, these neurons may remain alive after SCI, 
although the spinal tracts may be interrupted and disorganized at the lesion site, and 
myelin would shift from its highly structured physiological state to that of a chaotic 
net. Several components of the myelin net are potent inhibitors for axonal growth: 
Nogo A, B and C; MAG; and oligodendrocyte myelin glycoprotein OMgp or MOG (Filbin, 
2003; He and Koprivica, 2004; Moreno-Flores and Avila, 2010; Oertle and Schwab, 
2003; Raisman, 2004; Yang and Strittmatter, 2007; Yiu and He, 2003). The receptors of 
these molecules present in the presumptive regenerating axons also play a 
fundamental role in regeneration: NgR, NgR2 and NgR3 (Yiu and He, 2006). This picture 
is becoming more complete as new molecules are identified as myelin receptors: the 
human leukocyte immunoglobulin-like receptor B2 (LILRB2, a member of the B type 
subfamily of LILR receptors) and its orthologue in mice, the paired immunoglobulin-like 
receptor B (PirB) that is an MHC class 1 receptor (Atwal et al., 2008) and references 
therein]. Nogo, MAG and OMgp bind to NgRs and PirB (Atwal et al., 2008), and MAG 
also to binds to NgR2 but not NgR3 (Lauren, Airaksinen, Saarma, & Timmusk, 2003; 
Lauren et al., 2007; Venkatesh et al., 2005). NgR couples to LINGO 1 and p75NTR or 
TAJ/TROY, constituting the complete receptor complex (Domeniconi et al., 2002; 
Fournier, GrandPre, & Strittmatter, 2001; Liu, Fournier, GrandPre, & Strittmatter, 
2002; Mi et al., 2004; Park et al., 2005; Shao et al., 2005; Wang, Kim, Sivasankaran, 
Segal, & He, 2002; Wong et al., 2002). This receptor complex mediates the signalling of 
its ligands, in turn modulating the activity of the Rho GTPases and inhibiting axonal 
regeneration (Niederost, Oertle, Fritsche, McKinney, & Bandtlow, 2002; Kubo, 
Yamaguchi, Iwata, & Yamashita, 2008; Kubo and Yamashita, 2007; McKerracher and 
Higuchi, 2006; Mimura et al., 2006; Yamashita, Higuchi, & Tohyama, 2002; Yamashita, 
Tucker, & Barde, 1999). The inhibitory role of Nogo proteins after SCI has been studied 
thoroughly, showing that these molecules block axon regeneration through NgRs 
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(Moreno-Flores and Avila, 2010). More recently, H2-Kb and H2-Db, two ligands of PirB, 
were associated to a worse prognosis following CNS injury. In this context, H2-Kb and 
H2-Db KO mice, or those lacking the PirB receptor, develop a smaller infarct volume 
and they experiment better motor recovery, probably due to weakened astrocyte 
activation and to enhanced corticospinal projection into the denervated areas in 
animals subjected to focal ischemia (Adelson et al., 2012). 
Additionally, some other “negative” influences on axonal growth that direct axons to 
their appropriate territories during development, are also disorganized in the scar, 
such as axon guidance ligands and receptors, impeding axonal growth through the 
lesion site. In the glial scar, secreted and membrane semaphorins/receptors are 
expressed, like sema3A and sema4D/Plexin B1, as well as Eph receptors/ligands such 
as EphB3/EphrinA4 (Cregg et al., 2014; Fawcett, Schwab, Montani, Brazda, & Muller, 
2012; Silver and Miller, 2004). 
Finally, another important problem that leads to deficient axon regeneration is the lack 
of trophic support for the injured CNS neurons. In experimental models in vivo, the 
neurotrophins, FGF-2 and GDNF can all promote regrowth of different axonal tracts 
(Bradbury et al., 1999; Eggers et al., 2008; Kwon et al., 2007; Mills, Allchorne, Griffin, 
Woolf, & Costigan, 2007; Ramer, Duraisingam, Priestley, & McMahon, 2001; Ramer, 
Priestley, & McMahon, 2000; Ramer et al., 2002; Romero, Rangappa, Garry, & Smith, 
2001; Schnell, Schneider, Kolbeck, Barde, & Schwab, 1994; Tang, Cai, Nelson, Peng, & 
Smith, 2004; Tang, Heron, Mashburn, & Smith, 2007; Vavrek, Girgis, Tetzlaff, Hiebert, & 
Fouad, 2006; Zhang, Dijkhuizen, Anderson, Lieberman, & Verhaagen, 1998). 
Additionally, when fibroblasts, SchCs and OECs are combined with growth factors or 
engineered to express neurotrophins, they effectively promote axon 
regrowth/plasticity of different neurons and spinal tracts (Bregman et al., 2002; 
Coumans et al., 2001; Grill et al., 1997; Grill et al., 1997; Liu et al., 1999; Menei, 
Montero-Menei, Whittemore, Bunge, & Bunge, 1998; Ruitenberg et al., 2003; 
Ruitenberg et al., 2005; Runyan and Phelps, 2009; Tuszynski et al., 1998; Xu, Guenard, 
Kleitman, Aebischer, & Bunge, 1995; Zhang et al., 2009), inducing functional recovery 
(Grill et al., 1997; Liu et al., 1999; Ruitenberg et al., 2003). 
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5.2 І  OEC transplantation in animal models of SCI 
Only some cell populations in the nervous system can continuously regenerate 
throughout adult life, such as the olfactory receptor neurons in the context of the OEC 
environment (Ruitenberg and Vukovic, 2008; Schwob et al., 2016). Since OECs usually 
surround these growing olfactory axons in the adult mammalian CNS, it is reasonable 
to hypothesise that they might facilitate CNS axon regrowth after injury (Barnett and 
Chang, 2004; Barnett and Riddell, 2007; Franssen et al., 2007; Moreno-Flores et al., 
2002; Moreno-Flores and Avila, 2010; Raisman, 2001; Raisman and Li, 2007; Richter 
and Roskams, 2008). In recent years, the use of OECs to treat SCI has been studied 
extensively, and in fact, several studies in different models have confirmed their 
neuro-reparative capacity in response to acute (Garcia-Alias, Lopez-Vales, Fores, 
Navarro, & Verdu, 2004; Leng, He, Li, Wang, & Cao, 2013; Li et al., 1997; Li, Field, & 
Raisman, 1998; Lopez-Vales, Garcia-Alias, Fores, Navarro, & Verdu, 2004; Lopez-Vales 
et al., 2006; Lu et al., 2001; Ramon-Cueto et al., 1998; Ramon-Cueto et al., 2000) and 
delayed/chronic lesions (Lopez-Vales et al., 2006; Lopez-Vales, Fores, Navarro, & 
Verdu, 2007; Lu, Feron, Mackay-Sim, & Waite, 2002; Plant, Christensen, Oudega, & 
Bunge, 2003). Their reparative ability is due to a combination of several factors (see 
section “Molecular features and cellular functions of OECs”). OECs can preserve the 
lesion area by dampening the inflammatory response, as well as by decreasing 
cavitation and the size of the glial scar. They may also promote angiogenesis and axon 
regrowth/plasticity in different tracts, or remyelination, in some cases in association 
with functional recovery (Andrews and Stelzner, 2007; Garcia-Alias et al., 2004; 
Lakatos, Franklin, & Barnett, 2000; Lakatos, Barnett, & Franklin, 2003; Lopez-Vales et 
al., 2004; O'Toole, West, & Chuah, 2007; Plant et al., 2003; Ramer et al., 2004; 
Ruitenberg et al., 2003; Ruitenberg et al., 2005; Takami et al., 2002). Both OM and OB 
OECs have neuroreparative capacity, being able to promote a decrease in the size of 
the lesion and of the cavity in the SC. However, they exhibit different properties in 
terms of promoting sprouting of spinal axonal tracts, integration and migration 
(Richter et al., 2005) and see section “Molecular features and cellular functions of 
OECs”). In the next sections we will consider each of these different functional aspects 
of OECs after transplantation in SCI animal models. 
Page 22 of 102
John Wiley & Sons, Inc.
GLIA
23 
5.2.1 Interaction of OECs with the glial scar 
As the glial scar is one of the biggest barriers to neuroregeneration, interventions to 
prevent or limit its development will have a strong impact on regenerative success. 
Thus, the outgrowth of new axons must occur in a microenvironment rich in inhibitory 
factors (see section “CNS Regeneration: a brief overview”) and the balance of these 
with promoting factors presented by OECs will define the final response. In contrast to 
SchCs, OECs interact with astrocytes and meningeal cells, and they can mingle with 
astrocytes in culture and in the glial scar (Andrews and Stelzner, 2007; Franssen, Roet, 
de Bree, & Verhaagen, 2009; Lakatos et al., 2000; Li, Li, & Raisman, 2005; Moreno-
Flores et al., 2006; Ramer et al., 2004; Santos-Silva et al., 2007). Recently, light was 
shed on this fundamental difference between these cell types, even though they are 
both derived from the neural crest. It was first demonstrated that the capacity to form 
SchC-astrocyte boundaries depended on the secretion of highly sulphated heparan 
sulphate proteoglycans (HSPGs), which was higher in SchCs than in OECs. These 
boundaries were disrupted with antibodies against FGF1 and FGF9, signalling through 
FGF receptor-IIIb, an event that is modulated by the sulphation of HSPGs and that is 
driven by the weaker expression of the extracellular 6-O-endosulfatase enzymes Sulf 1 
and Sulf2 by SchCs (Higginson et al., 2012). SchCs engineered to express both 
sulphatases acquire the ability to integrate with astrocytes without forming 
boundaries, enhancing their integrin-dependent motility in the presence of astrocytes 
(O'Neill et al., 2017). These interesting findings have important implications to increase 
the effectiveness of cell therapy in SCI and CNS injuries. 
The OEC-astrocyte interaction implies a change in the scar, the outer membranes of 
OECs being able to form a continuum to bridge the gap. This may be a crucial event for 
the regrowth of axons within the lesion area after SCI. OECs also produce extracellular 
matrix proteases in parallel with their ability to penetrate the gliotic tissue of the SC, 
which correlates with corticospinal tract regeneration (Pastrana et al., 2006). 
Moreover, it has been demonstrated that OECs can reduce astrocytic reactivity and 
CSPG expression (Garcia-Alias et al., 2004; Lakatos et al., 2003; O'Toole et al., 2007). 
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All these properties of OECs could make removal of the glial scar unnecessary, since a 
positive balance of membrane and secreted stimulating factors provided by OECs 
would decrease the inhibitory tendency, permitting axon repair. As such, OECs should 
be distributed over the lesion and thus, their capacity to migrate would be 
fundamental. Indeed, OEC migration has been reported in the unlesioned SC (Deng et 
al., 2006; Lee et al., 2004), being extensive in the X-irradiated SC and brain (Imaizumi, 
Lankford, Waxman, Greer, & Kocsis, 1998; Lankford, Sasaki, Radtke, & Kocsis, 2008; 
Lankford, Brown, Sasaki, & Kocsis, 2014). Although migration in SCI was initially 
described (Ramon-Cueto et al., 1998), the capacity of OECs to migrate seems to be 
limited or inexistent in several SC lesion models depending on the approaches adopted 
(Andrews and Stelzner, 2007; Collazos-Castro, Muneton-Gomez, & Nieto-Sampedro, 
2005; Lee et al., 2004; Lu et al., 2006; Moreno-Flores et al., 2006; Pearse et al., 2007; 
Ramer et al., 2004). When OECs were transplanted in a transection context and 
studied by magnetic resonance imaging (MRI), these cells failed to cross the gap of the 
SC (Lee et al., 2004). However, cells transplanted at the stump migrated a short 
distance, half that in the normal SC. Similar limited migration has been described in 
another study, yet restricted to only a small number of cells (Pearse et al., 2007), 
whereas even shorter migration distances (≤ 1mm) were reported elsewhere (Deng et 
al., 2006; Ramer et al., 2004; Reginensi et al., 2015; Richter et al., 2005). 
The site of transplantation also varied in these studies, with OECs transplanted at the 
lesion site (Collazos-Castro et al., 2005; Pearse et al., 2007; Ramer et al., 2004; Richter 
et al., 2005), outside the injury (Pearse et al., 2007; Reginensi et al., 2015; Richter et 
al., 2005) or both at and outside the lesion site, rostrally and caudally (Andrews and 
Stelzner, 2007; Moreno-Flores et al., 2006). In a hemisection model performed 
contralateral, and several mm rostral to the transplantation site, significant OEC 
migration was reported, albeit less than in the intact SC (Deng et al., 2006). OEC 
migration from sites rostral and caudal to the lesion site was also reported elsewhere, 
being higher for LP cells than for those from the OB (Richter et al., 2005). In our own 
experience, we detected limited migration of OECs in the dorso-ventral axis after 
injection at several sites, into the lesion and 1 mm caudal or rostral (Moreno-Flores et 
al., 2006). Limited migration was also reported in a subsequent study and the injection 
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pressure influenced in the distribution of the cells (Andrews and Stelzner, 2007). 
However, when we quantified rostral and caudal migration (around 1 mm) in a SCI 
contusion model in which cells of an OEC line were injected laterally on both sides of 
the lesion, migration by modified OECs secreting the Nogo receptor ectodomain was 
enhanced (around 2 mm: (Reginensi et al., 2015). Therefore, it generally seems that 
OECs can migrate better in an uninjured SC than in the lesioned one. OECs seem to be 
able to migrate to the lesion site but when injected directly into the epicentre of the 
lesion, they fail to migrate out and are unable to cross the gap in some contexts. 
With regards the factors that aid the migration of these cells, reactive astrocytes in the 
glial scar attract OECs in a model of SC hemisection by secreting TNF-α (Su et al., 
2009). Additionally, GDNF can promote OEC migration in vivo and in vitro (Cao et al., 
2006). Our previous results reinforce the idea that most of the factors inhibiting axon 
elongation and regrowth after lesion may also affect OEC migration (Reginensi et al., 
2015). In fact, all the molecules thought to inhibit OEC migration—NogoA, CSPGs, 
fibulin-3, and Slit2— are overexpressed in CNS scars after lesion (Cregg et al., 2014; He 
and Koprivica, 2004; Lukovic et al., 2014; Nocentini et al., 2012; Reginensi et al., 2015; 
Vukovic et al., 2009a). 
In summary, multiple factors seem to be fundamental in choosing where to transplant 
cells. The role of OECs/glial scar interactions or the idea of bridging the gap are not 
negligible. For example, the cells in a transection model are probably not going to be 
able to cross the gap if this is not filled or bridged in some way. The best way to carry 
out transplantation is probably to use several injection/transplantation sites, in 
particular the epicentre of the lesion in conjunction with other additional points. We 
will address these issues further in the section “OEGS to cure SCI: Clinical studies”. 
5.2.2 Axon repair and functional recovery 
In animal models of SCI (Table 3), OECs have the ability to promote axon 
regrowth/sprouting/sparing (Chuah et al., 2004; Garcia-Alias et al., 2004; Ibrahim, 
Kirkwood, Raisman, & Li, 2009; Imaizumi, Lankford, & Kocsis, 2000; Li et al., 1997; Li et 
al., 1998; Lopez-Vales et al., 2006; Lopez-Vales et al., 2007; Lu et al., 2001; Lu et al., 
2002; Moreno-Flores et al., 2006; Plant et al., 2003; Ramon-Cueto and Nieto-
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Sampedro, 1994; Ramon-Cueto et al., 1998; Ramon-Cueto et al., 2000; Richter et al., 
2005). In all these studies, the axons re-growing from supraspinal or DRG neurons 
were assessed and they were identified using retrograde, anterograde and 
transganglion tracers, such as fluorogold/fluororuby, wheat germ agglutinin-
horseradish peroxidase, Dil, biotinylated dextran amine or cholera toxin subunit B 
((Chuah et al., 2004; Ibrahim et al., 2009; Li et al., 1997; Li et al., 1998; Lopez-Vales et 
al., 2006; Lopez-Vales et al., 2007; Lu et al., 2001; Lu et al., 2002; Moreno-Flores et al., 
2006; Plant et al., 2003; Ramon-Cueto et al., 1998; Ramon-Cueto et al., 2000; Toft, 
Scott, Barnett, & Riddell, 2007). Moreover, markers like GAP-43, calcitonin gene-
related peptide (CGRP), neurofilament, serotonin and noradrenalin have been used to 
identify axons in contact with OEC grafts (Gorrie et al., 2010; Li, Decherchi, & Raisman, 
2003; Lu et al., 2001; Lu et al., 2002; Plant et al., 2003; Ramon-Cueto and Nieto-
Sampedro, 1994; Ramon-Cueto et al., 1998; Ramon-Cueto et al., 2000; Richter et al., 
2005). Additional evidence of OEC-induced axon regrowth into and through the lesion 
site comes from electrophysiological studies (see below and(Garcia-Alias et al., 2004; 
Ibrahim et al., 2009; Imaizumi, Lankford, Burton, Fodor, & Kocsis, 2000; Imaizumi et al., 
2000; Li et al., 2003; Li, Li, Chen, Chang, & Duan, 2011; Lopez-Vales et al., 2004; Lopez-
Vales et al., 2006; Lopez-Vales et al., 2007; Lu et al., 2001; Toft et al., 2007). 
It is clearly fundamental to achieve functional recuperation in transplanted animals to 
consider OEC transplants an effective therapeutic strategy to treat SCI. One of the first 
studies using OECs transplants in SCI (complete transection) assessed a long survival 
time and after 7 months, the transplanted rats had regained the ability to use their 
hind limbs for scaling and they recovered a reflex to skin stimulation (Ramon-Cueto et 
al., 2000). Subsequent studies showed functional recovery after OEC transplantation 
using the Basso, Beattie, Bresnahan locomotor scale (BBB) and several other 
behavioral motor and sensory tests. Functional recovery paralleled the anatomical 
findings in some such studies, supporting OEC induced axon repair even after chronic 
SCI (DeLucia et al., 2003; Garcia-Alias et al., 2004; Ibrahim et al., 2009; Li et al., 2003; Li 
et al., 2011; Lopez-Vales et al., 2006; Lopez-Vales et al., 2007; Lu et al., 2001; Lu et al., 
2002; Moreno-Flores et al., 2006; Plant et al., 2003; Ramon-Cueto et al., 2000; 
Ruitenberg et al., 2003). However, it was not possible to demonstrate such a 
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relationship between functional recovery and axon regrowth with OM cells 
(Yamamoto, Raisman, Li, & Li, 2009), and in other studies functional recovery was 
poorer, although some compensatory mechanisms in movement appeared after OEC 
transplantation (Ruitenberg et al., 2005). 
Electrophysiological studies have been used to evaluate OEC transplantation, with 
animals showing some recovery of action or evoked potentials (Garcia-Alias et al., 
2004; Ibrahim et al., 2009; Imaizumi et al., 2000; Imaizumi et al., 2000; Lopez-Vales et 
al., 2004; Lopez-Vales et al., 2006; Lopez-Vales et al., 2007; Li et al., 2003; Li et al., 
2011; Lu et al., 2001; Toft et al., 2007), in several cases correlated with functional 
recovery (Garcia-Alias et al., 2004; Ibrahim et al., 2009; Li et al., 2003; Lopez-Vales et 
al., 2004; Lopez-Vales et al., 2006; Lopez-Vales et al., 2007; Lu et al., 2001; Toft et al., 
2007). However, it remains unclear if functional recovery mediated by OEC transplants 
reflects appropriate reconnections of severed nerve fibres, or if they are due to other 
indirect mechanisms in incomplete lesions. The preservation of surviving fibres or the 
formation of alternative pathways may also be responsible for the functional 
amelioration, for example collateral sprouting and reconnection through long 
propiospinal interneurons (Deumens, Koopmans, & Joosten, 2005; Bareyre et al., 2004; 
Toft et al., 2007; Yamamoto et al., 2009). 
OECs can act directly as a physical substrate for neurite/axon growth, this being more 
effectively promoted when the OECs are in close contact with neurons, as 
demonstrated in vitro (Chung et al., 2004; Moreno-Flores et al., 2002; Moreno-Flores 
et al., 2003b; Sonigra, Brighton, Jacoby, Hall, & Wigley, 1999) and in vivo (Li et al., 
2005). OECs seem to be able to extend cytoplasmic processes and generate channel-
like structures across the astroglial borders of the lesion (Andrews and Stelzner, 2007), 
which would be useful for the growth of regenerating axons. These channels have an 
outer basal lamina overlaid by fibroblasts and a bare inner surface in contact with 
nerve fibres, this being postulated as a determinant for their regenerative capacity 
formulated as the “pathway hypothesis” (Li et al., 2005). The capacity of OECs to 
penetrate and to digest the glial scar would permit them to establish bridges, 
generating a pro-regenerative substrate (for references see the section “Interaction of 
OECs with the glial scar“). In addition, their ability to secrete neurotrophic factors 
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seems to be fundamental to this effect (Lipson et al., 2003; Pastrana et al., 2007; 
Pellitteri, Spatuzza, Russo, & Stanzani, 2007; Pellitteri, Spatuzza, Russo, Zaccheo, & 
Stanzani, 2009; Sasaki, Hains, Lankford, Waxman, & Kocsis, 2006). Their secretory 
profile (see “Molecular features and cellular functions of OECs”) might account for the 
capacity of OEC grafts to facilitate the regeneration of some spinal tracts but not 
others in the lesioned SC, depending on their trophic requirements (Jones et al., 2001; 
Moreno-Flores et al., 2002). However, this profile can be altered or improved by gene 
transfer (Ruitenberg et al., 2005; Ruitenberg et al., 2003). The secretion of other 
factors would also contribute to the neuroregenerative properties of OECs (Pastrana et 
al., 2006; Simon et al., 2011). Adult neurons in the CNS are normally surrounded and 
stabilized by the PNN, which inhibits neurite outgrowth (Celio et al., 1998; Rhodes and 
Fawcett, 2004). It was previously demonstrated that MMP2 can also digest CSPGs of 
the PNN in vitro (Fig. 4) and enhance axon growth (Pastrana et al., 2006). Moreover, 
MMP2 can digest CSPGs in the glial scar (Fig. 4; see section “Interaction of OECs with 
the glial scar“), and the ability to secrete MMP2 and other proteases like PAI-1 was 
also fundamental for the proregenerative properties of OECs (Pastrana et al., 2006; 
Simon et al., 2011). Indeed, MMP2 production correlates with corticospinal tract 
regeneration in vivo (Moreno-Flores et al., 2006; Pastrana et al., 2006). 
Finally, the Scavenger receptor class B member 2 (SCARB2) type III glycoprotein is 
produced by OECs, which is key for their neurite growth ability (Roet et al., 2013; Roet 
and Verhaagen, 2014). This protein is located primarily in the limiting membranes of 
lysosomes and endosomes. SCARB2 gene transfer can mediate regeneration of dorsal 
column sensory axons in the injured SC (Roet et al., 2013; Roet and Verhaagen, 2014), 
and this action is probably related to lipid transfer mechanisms and the synthesis of 
cholesterol-containing lipoproteins. Glial cells secrete lipoproteins containing 
cholesterol, and they can promote neurite outgrowth and synapse formation in 
cultures of retinal ganglion cells and DRG neurons (Handelmann, Boyles, Weisgraber, 
Mahley, & Pitas, 1992; Hayashi, Campenot, Vance, & Vance, 2009; Mauch et al., 2001). 
The transfer of lipids and cholesterol to growing axons is important for membrane 
synthesis during regeneration after injury (Boyles et al., 1989; Jurevics, Bouldin, Toews, 
& Morell, 1998; Li, Fowler, Neil, Colton, & Vitek, 2010). It is known that damage in the 
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CNS leads to the synthesis of proteins involved in lipid metabolism and cholesterol, and 
that pharmacological or genetic interference with cholesterol reuse dampens local 
axonal growth (Roet and Verhaagen, 2014). 
In summary, OECs can guide and stimulate the growth of olfactory axons towards their 
targets, and they can provide and regulate the lipid transfer necessary for this process 
(Roet and Verhaagen, 2014). As such, it can be inferred that one of the main 
mechanisms for OEC-dependent axon repair in the CNS may rely on lipid metabolism in 
these cells and in their ability to transfer them to the growing axons. 
5.2.3 Myelination 
Demyelination is widespread in the sub-chronic phase of the SCI, at 7 DPI (Blight, 1985; 
Plemel et al., 2014), and it might block action potentials (Blight, 1983) or render axons 
more susceptible to degeneration (Irvine and Blakemore, 2008; Plemel et al., 2014). 
However, axonal conduction can be achieved without remyelination, even if denuded 
axons persist in association with demyelinating lesion (Felts, Baker, & Smith, 1997), 
and deficits in electrical conduction may occur that are not due to demyelination. 
Significantly, such acute deficiencies were not evident contralateral to the lesion but 
they developed 1-2 weeks later, and they persisted in chronic states when 
remyelination should have taken place (Arvanian et al., 2009; Plemel et al., 2014). 
There are many issues to clarify regarding the persistence of oligodendrocyte death 
(over weeks) and demyelination after SCI. Therefore, remyelination as an intervention 
strategy after SCI remains controversial, even though it is generally considered an 
important therapeutic target (Plemel et al., 2014). Hence, in this section we will 
consider the capacity of OECs to produce myelination, directly or indirectly, implicating 
other cells such as SchCs. 
It has been demonstrated that foetal OECs have the ability to myelinate DRG neurites 
in vitro, with these cells having different growth requirements to SchCs with regards 
the assembly of a basal lamina (Devon and Doucette, 1992; Devon and Doucette, 
1995). From those initial studies, it was then demonstrated that OECs can directly 
myelinate axons after SCI (Akiyama, Lankford, Radtke, Greer, & Kocsis, 2004; Imaizumi 
et al., 2000; Imaizumi et al., 2000; Lankford et al., 2008; Lankford et al., 2014; Sasaki, 
Lankford, Zemedkun, & Kocsis, 2004; Sasaki, Li, Lankford, Radtke, & Kocsis, 2007). This 
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was shown with engineered green fluorescent protein (GFP), alkaline phosphatase-
expressing OECs, transgenic pig OECs expressing the human complement inhibitory 
protein CD59, or with OECs preloaded with 5- (and 6)-carboxyfluorescein diacetate 
succinimidyl ester. When transplanted, these OECs were able to myelinate the majority 
of axons in a peripheral-like manner, about half of which were associated with 
compacted myelin (Sasaki et al., 2004). Further evidence came from using transgenic 
mice expressing GFP under the control of CNPase promoter. This fluorescent protein 
was expressed in the OB in vivo and in culture, co-localizing with the OEC marker, 
p75NTR. When transplanted after sciatic nerve transection, these GFP-expressing OECs 
were associated to and myelinated the regenerating peripheral nerve (Radtke, Sasaki, 
Lankford, Gallo, & Kocsis, 2011). Furthermore, OEC transplantation has been shown to 
promote remyelination in models of SC demyelination, both in rodents and primates 
(Akiyama et al., 2004; Barnett et al., 2000; Franklin, Gilson, Franceschini, & Barnett, 
1996; Imaizumi et al., 1998; Lankford et al., 2008; Radtke et al., 2004; Sasaki et al., 
2006). 
However, other conflicting findings have also been presented, for example when 
invasive SchCs appeared to be responsible for remyelination as opposed to engineered 
Lac-Z expressing OECs (Boyd, Lee, Skihar, Doucette, & Kawaja, 2004). These OECs 
might have attracted these exogenous SchCs to the SC and indeed, OEC conditioned 
medium may be a chemoattractant for SchCs in vitro, with NGF representing an 
important driver of this effect (Cao et al., 2007). Moreover, oligodendrocyte precursor 
proliferation has been proposed to influence remyelination after SCI (Czepiel, 
Boddeke, & Copray, 2015; Jiang et al., 2008), such that the activation of this glial 
lineage after OEC transplantation may be in part involved in remyelination, together 
with SchCs (Masgutova, Savchenko, Viktorov, Masgutov, & Chelyshev, 2010). 
5.2.4 Combining OECs with other treatments 
As indicated above, OECs can induce axonal repair and/or functional improvement in 
SCI, alone or when combined with SchC grafts, SchCs and chondroitinase, or with SchCs 
combined with elevated cAMP (Bunge, 2008; Fouad et al., 2005; Fouad, Pearse, 
Tetzlaff, & Vavrek, 2009; Ramon-Cueto et al., 1998; Takami et al., 2002; Vavrek, 
Pearse, & Fouad, 2007). However, in some SCI models, SchC grafts and OECs have a 
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similar capacity to promote functional/electrophysiological recovery and/or 
regeneration of certain axonal tracts (Garcia-Alias et al., 2004; Imaizumi et al., 2000; 
Imaizumi et al., 2000), improving the efficacy of SchCs on occasion (Takami et al., 
2002).  
OECs have also been used in conjunction with several kinds of stem cells and in a 
model of incomplete SCI, better BBB functional recovery was achieved by transplanting 
foetal neural stem cells along with adult OECs (Wang et al., 2010). In addition, co-
transplantation of foetal (Deng et al., 2008) or adult OECs (Wu et al., 2015) with adult 
human (Deng et al., 2008) or rat (Wu et al., 2015) BM-MSCs had a beneficial effect in a 
contusion SCI model, as judged by histopathological and functional evaluation (BBB 
and transcranial magnetic motor-evoked potentials). Hind limb recovery may have 
been related to a significant anti-apoptotic effect (Wu et al., 2015), although significant 
effects on tissue sparing have been seen and functional tests (BBB) improved following 
transplantation of juvenile LP-OECs or BM-MSCs to treat compressive SCI (Amemori, 
Jendelova, Ruzickova, Arboleda, & Sykova, 2010). In this study there were no 
significant differences between the individual treatments and combining both types of 
cells (Amemori et al., 2010). 
In a study combining glial scar ablation, LP grafts and transplantation of cultured LP-
OECs from adult rats prevented scar reformation, along with an increase in the 
repaired tissue (transplanted tissue/cells integration), a marked reduction or even the 
disappearance of the lesion cavity, and a significant increase in the P0 positive 
myelination. Surprisingly, there was no significant functional restoration according to 
the BBB (Zhang, Huang, Gates, & Holmberg, 2011). Several possibilities for these 
effects were discussed but the correct interpretation should probably take into 
account that the impairment in the BBB after the contusion lesion was not very large in 
this study when compared to similar SCI studies (Deng et al., 2008; Wu et al., 2015). 
Moreover, values pre-surgery were not reported nor was a sham operated control 
group used. 
Carlos Lima’s therapeutic approach for SCI involved OM transplantation (see section 
“OECs to cure SCI: Clinical studies”), based on the idea of that this tissue is composed 
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of multiple cell types, including OECs and stem cells. As such, the use of the OM avoids 
the need to expose cells to an artificial tissue culture environment (Lima et al., 2006). 
In recent years, a stem cell-like population has been identified in the OE and another 
one in the LP (Tome et al., 2009). OM-MSCs have been isolated from the LP and 
characterized in different laboratories (Delorme et al., 2010; Feron et al., 2013; Girard 
et al., 2011; Lindsay et al., 2010; Lindsay et al., 2013; Lindsay and Barnett, 2017). 
Transplanted olfactory MSCs differentiated into neurons and stimulated 
neuroplasticity after lesions in the hippocampus promoted neurogenesis (Nivet et al., 
2011). These cells could produce dopaminergic neurons in a rat model of Parkinson 
disease (Murrell et al., 2008) and recently, it was demonstrated that OM-MSCs from 
the LP promote remyelination and the earlier recovery of gait coordination in a model 
of incomplete SCI (Lindsay et al., 2017). OM-MSCs secrete factors that modulate OEC 
behaviour in vitro, enhancing the extension of processes and their alignment along 
neurites, thereby promoting axon sheathing (Lindsay et al., 2013; Lindsay et al., 2016). 
OM-MSC conditioned medium promoted myelination in vitro (Lindsay et al., 2013). 
OEC conditioned medium can induce neural stem cells, umbilical cord blood MSCs and 
OM-MSCs to differentiate into neurons (Duan et al., 2011; Ge, Liu, Liu, & Lu, 2016; 
Zeng et al., 2013). Indeed, the combined use of OM-OECs with OM-MSCs was 
proposed as a novel strategy for SCI via autologous transplantation of both cell types 
(Ge et al., 2016). 
Finally, combining OEC transplantation with other treatments may improve the 
outcome of SCI therapy. A combination of OECs with local (in the red nucleus) or 
systemic cAMP (subcutaneous infusion of Rolipram) was used in a model of 
dorsolateral funiculus crush. Although OECs could attenuate the astrocytic reaction 
and retraction of the rubrospinal axons, producing a tendency towards a smaller 
lesion, neither OECs alone nor the combined treatment could promote regrowth of the 
axotomized axons through the lesion site (Bretzner et al., 2010). The therapeutic effect 
of combining OEC transplantation with acidic fibroblast growth factor (aFGF) has also 
been evaluated using complete SC transection (Botero, 2015; Gomez, 2009). Local 
reparative activation was evident in the injured SC tissue, leading to functional 
recovery as evaluated using the BBB scale (Botero, 2015; Gomez, 2009). This 
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combination functioned in a similar way in chronic and acute SCI (Botero, 2015) when 
evaluated using a neurological assessment (Gomez et al., 2015). Transplanted rats 
showed motor and sensory recovery in both the acute and chronic phase. Confocal 
microscopy established that this combined treatment induced axon repair, with axons 
traversing the cavity and joining the cranial and caudal segments of the lesion. 
Transplantation/aFGF also decreased the size of the glial scar and the number of 
reactive astrocytes. The ultrastructural analysis showed remyelination compatible with 
central and peripheral myelin. These results confirm the positive effect of transplanting 
OECs and aFGF to induce SCI recovery (Botero, 2015). 
 
 
6  І  OECs TO CURE SCI: CLINICAL STUDIES 
Studies with OECs have not only been performed in experimental animal models but a 
moderate number of clinical studies have also been performed on humans in several 
countries. The human foetal OB is a viable source of OECs for heterologous 
transplantation, as has been used in China. Although these heterologous transplants 
have been performed on a large number of SCI patients (Huang et al., 2009), and in 
patients with amyotrophic lateral sclerosis or Friedreich’s Ataxia, it is difficult to 
ascertain the contribution of the OEC component in these bulb-derived cell mixtures. 
This clinical approach has also raised ethical and legal issues in other countries (Watts, 
2005). Several problems have to be considered when evaluating the results of the use 
of this treatment in China: 
-The source of the foetal OB-derived cells for the patient treatment must be obtained 
in accordance with applicable Chinese guidelines, both institutional and governmental. 
-The transplanted foetal OB-derived cells were not well characterized in most cases 
(see exception below: (Guest, Herrera, & Qian, 2006). 
-A rigorous clinical study was not performed, incorporating the corresponding controls 
or with a complete evaluation of the patients before and after transplantation surgery. 
-This surgery was offered to all patients willing a travel to China and pay for a cure for 
their condition. 
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-There has been no systematic follow-up by independent clinicians. 
Nevertheless, there have been some independent evaluations of this procedure and in 
one of these the results from seven patients transplanted in China were disappointing, 
with no functional improvement and some perioperative morbidity (Dobkin, Curt, & 
Guest, 2006). It was indicated that the procedures used on this group did not 
necessarily meet international standards for either safety or efficacy, and it was 
concluded that physicians should not recommend this procedure to their patients. By 
contrast, a positive effect was reported in one complete tetraplegic C3 ASIA A patient 
transplanted with foetal OB-derived cells in China (cultured cells labelled for nestin and 
GFAP). The young patient (18 years old) improved one ASIA (American Spinal Injury 
Association) motor grade shortly after transplantation (48 hours), while a sensory 
improvement occurred 4 days after the procedure and then changed slowed. The 
patient shifted to C5 motor and C4 sensory complete tetraplegia and it was thought 
that the remaining intact fibres were implicated in these early responses, although the 
need for further independent analysis was recognised (Guest et al., 2006). 
Another study involving the same team in China involved the use of OEC in 
combination with SchCs, recruiting several patients to a double blind clinical study. The 
benefits of using both types of cells and their combination were examined for 
transplantation in cervical, chronic, complete SCI. In 2014, they reported results from 5 
patients (3 received OECs, 1 SCs and 1 OECs+SCs) and two control cases. The 
neurological assessments were performed according to the American Spinal Injury 
Association guidelines, and using the International Association of Neurorestoratology 
(IANR) Functional Rating Scales in combination with electrophysiological tests. 
Although this study is prospective and very preliminary, all five patients showed very 
significant functional improvement at 6 months of follow-up (Chen et al., 2014). 
Autologous transplants have been carried out in seven patients using OM grafts in 
Portugal, all of which showed improvement in their ASIA motor scores. Two ASIA A 
patients became ASIA C (Lima et al., 2006), although some adverse effects were 
reported, such as a sensory decline in one patient and transient pain that responded to 
medication. A collaborative Indian pilot study was not able to demonstrate efficacy in 
five chronic, motor complete SCI patients (Chhabra et al., 2009). Moreover, a later 
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study that enrolled 20 patients that underwent preoperative rehabilitation with no 
change in the ASIA impairment scale (AIS). Rehabilitation was maintained after the 
procedure, with one patient suffering aseptic meningitis and some minor adverse 
effects occurring in the other four patients. AIS grades improved in 11 of the 20 
patients, and some of them improved in terms of new voluntary electromyography 
responses (15 patients) and somatosensory evoked potentials (4 patients: (Lima et al., 
2010). However, as in the case of the Chinese studies, these results were not 
independently confirmed and raised some doubts in the field (personnel 
observations). More evidence will be needed in the future to support this treatment. 
Other groups have worked with mucosal-derived cultured OECs and a phase I/IIa 
clinical trial was completed in Australia at The National Centre for Adult Stem Cell 
Research, Griffith University (Feron et al., 2005; Mackay-Sim et al., 2008). The main 
objective was to test the feasibility and safety of autologous transplantation of OECs to 
treat SCI in humans (Feron et al., 2005). The participants were three paraplegic males 
ranging from 18-55 years old, with stable and complete thoracic injuries, and three 
matched control patients. The patient’s OECs were grown and purified in vitro from 
nasal biopsies and the cells were characterized for the OEC markers (S100
+
 and GFAP
+
 
>95% and p75NTR
+
: 76-88%). Autologous cells were injected into the region of the 
damaged SC, employing a different number of cells in each patient: 12, 20 and 28 
million. An evaluation was made before transplantation and at regular intervals 
thereafter, including MRI, medical, neurological and psychosocial assessment, and a 
standard ASIA and Functional Independence Measure assessment. The participants 
were followed up for 3 years, concluding that the transplantation of autologous OECs 
is feasible and safe for SCI (Feron et al., 2005; Mackay-Sim et al., 2008). Although this 
clinical study is very preliminary, with the inclusion of only a few patients, functional 
recovery outcomes were also evaluated three years after transplantation. They found 
very modest findings, with no significant functional improvements except in one 
patient who showed an improvement over three segments in sensitivity (Mackay-Sim 
et al., 2008). However, they concluded that the procedure is feasible and safe, despite 
the inconvenience of the surgery and injection of the cells into the SC. Nevertheless, all 
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cell therapy clinical trials for SCI to date imply having to “touch” the SC again, with the 
corresponding risk to patients. 
Another group from Poland recently conducted a phase I clinical trial using autologous 
OM OECs and olfactory nerve fibroblasts (ONFs), comparing three transplanted 
patients to three controls (22-26 years old). Multiple injections (120-212) were used to 
transplant 1.8, 1.9 and 21.2 x10
6
 cells (with 10, 25.7 and 12% S100
+
 OECs, respectively), 
demonstrating the safety and feasibility of transplanting these cells. Additionally, 
functional improvements were demonstrated in two of the patients 1 year post-
transplantation, which shifted from ASIA A to ASIA C and ASIA B. The third patient 
experimented improved function of the first spinal segments below the injury, 
although he remained as ASIA A (Tabakow et al., 2013). However, the patient that 
improved from SCI ASIA A to C with OM transplantation had suffered a knife injury to 
the SC at T10-T11, a very particular type of lesion with unique features (Guest and 
Dietrich, 2015). 
In 2014 a clinical case was described in which autologous transplantation of OB 
OECs/ONFs was performed in a combinatorial treatment that included re-transection 
of the SC to eliminate scar tissue (Tabakow et al., 2014). The treated 38 year old 
patient presented a very particular type of penetrating SC lesion inflicted with a knife 
at the T9 level, similar to that of the patient in a previous study (Tabakow et al., 2013). 
This stab lesion left a thin rim of tissue on the right lateral column of the SC that 
connected both stumps of the cord, which were separated by 8 mm. The lesion 
produced an ASIA A functional deficit and even with rehabilitation, the deficit was 
stable 21 months after injury. The patient was treated in several ways, involving the 
removal of the glial scar (resection of the SC) and increasing the gap to 10 mm but 
maintaining the rim of tissue left after the lesion. The patient was treated with four 
strips of peripheral nerve taken from the patient’s sural nerve and 96 microinjections 
with a mixture of 5 x10
5
 OECs/ONFs cells (16% OECs p75NTR
+
) administered at 24 
different sites in the proximal and distal stump of the SC. The patient was continued to 
receive rehabilitation after surgery and there were no adverse effects in the 19 months 
after the procedure. Treatment produced a dramatic functional recovery, with the 
ASIA score of the patient shifting from complete SCI ASIA A to ASIA B 6 months post-
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surgery and finally, to ASIA C 11 months after the procedure. This score was 
maintained for a further 8 months, the last time point reported in the study. In 
addition to re-sectioning the lesion (to remove the inhibitory glial scar), in this case OB 
glial cells were combined with peripheral nerve bridges (composed of SchCs, ONFs and 
intercellular matrix) and intensive rehabilitation, introducing new parameters to the 
therapeutic strategy (Tabakow et al., 2014). The possible spontaneous recovery from 
this lesion was very low, taking into account that the patient had been under 
rehabilitation for 21 months prior to the intervention. Although in the first 13 months 
after lesion the patient was subjected to a number of different rehabilitation 
programs, these were incomplete and interrupted because of the need to treat 
different complications (infections, pressure ulcers and inflammation of the deep 
venous system of the lower limbs). Hence, the patient was subjected to an additional 
intense neurorehabilitation program for 8 months before receiving the experimental 
treatment to rule out spontaneous recovery. This programme did not produce an 
improvement in his condition, which only ameliorated impressively after the surgery. 
Therefore, and taking into account data from different studies on late spontaneous 
recovery (see discussion in Tabakow et al., 2014), the probability of spontaneous 
recovery in this patient was considered to be lower than 1% (Tabakow et al., 2014). 
However, examining the published data of this study more closely, there appeared to 
be possible decompression of a cystic structure that extended from the ventral cord to 
the dorsal arachnoid, maintained within the separated dural layers, which may have 
contributed to recovery in conjunction with the detethering of dural adhesions (Guest 
and Dietrich, 2015). With respect to the mechanisms underlying the functional 
changes, the possibility of unprecedented extent of axonal regeneration (10 cm) was 
considered, yet some concerns were raised about this matter. For example, the 
preserved tissue in the lateral column of the right SC might contain corticospinal axons 
that sent out collaterals, which could explain motor function recovery in the left leg 
(the latency of motor evoked potentials returning to the normal range). 
There are several issues that must be defined more accurately in relation to the clinical 
use of OECs. While the method of culture is fundamental, it may not be possible to 
standardize transplants for different subjects, which will make it even more difficult to 
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interpret new studies (Guest and Dietrich, 2015). The OM seems to be the most 
accessible tissue to prepare OECs for autologous transplantation. In fact, patients with 
SC transection who were transplanted with OM- (Tabakow et al., 2013) or OB-OECs 
(Tabakow et al., 2014) had similar outcomes, although peripheral nerve autografts 
were not used in the former. Thus, the need to use OB and peripheral grafts is not fully 
demonstrated in these studies (Guest and Dietrich, 2015).  
Transplantation of OM cells has produced different results to that of OB cells in the 
same rhizotomy model of lesion. This was attributed to the different composition of 
the cultures, which we have already addressed above, and to the low percentage of 
p75NTR positive OECs in the OM preparations (Ibrahim et al., 2014). However, in this 
respect it is necessary to consider the two clinical studies carried out in Poland 
(Tabakow et al., 2013; Tabakow et al., 2014). In the later study, a combined treatment 
was given to the patient with the transected SC, transplantation with 5 x 10
5
 OB-cells 
with 16% of p75NTR
+
 OECs (Tabakow et al., 2014), whereas  p75NTR and S100 
expression was used to identify OECs in the OEC/ONF mixture in the earlier study. The 
patient denoted as T1, also with the SC transected by a knife, recovered similarly to the 
patient in the 2014 study (ASIA A to C). Thus, both patients presented similar types of 
lesion (transection) and a similar degree of recovery. Patient T1 recovered the best of 
the three patients in this study with the OM cells grafted, even though he was 
transplanted with the smallest number of cells (1.8 x 10
6
) and with the lowest 
proportion of S100
+
 OECs (10%) of the three patients (Tabakow et al., 2013). The other 
two patients had a different type of lesion (compression), and they were transplanted 
with 1.9 x 10
6
 and 21.2 x 10
6
 OM cells, 25.7% and 12% of which were S100
+
, 
respectively. The functional recovery of these patients was poorer than both patients 
with the transection SC, although the total number of OECs they received was much 
higher. It is possible that surpassing a threshold of “true” OECs in the culture is 
sufficient to ensure an effect, and that specific factors related to each patient might 
account for these differences, such as the type of injury (Guest and Dietrich, 2015) or 
treatment. However, the mixed nature of the OM cultures, containing different cell 
types in addition to OECs, such as OM-MSC, ONFs and/or other p75NTR
-
 cells would do 
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necessary a more accurate characterization. This can be fundamental to achieve 
uniform, or at least more predictable, treatments. 
In some cases it might not be possible to establish a primary culture from the mucosa 
for different reasons. For example, in the case of the patient indicated above (Tabakow 
et al., 2014) it was due to chronic allergic sinusitis, although other possibilities include 
poor efficiency of the cultures (possibly due to the patient’s age), contamination of 
cultures, etc. (Moreno-Flores and Avila, 2006; Moreno-Flores and Avila, 2010). To 
obtain OECs from a patient’s OB has obvious problems related to the invasiveness of 
the surgery, even though it was accomplished with expertise in the work of Tabakow 
et al. The potential complications of craniotomy are well known, even using a 
minimally invasive approach, and they have also to be considered (Czyz, Tabakow, 
Hernandez-Sanchez, Jarmundowicz, & Raisman, 2015; Guest and Dietrich, 2015). 
The rationale behind our previous approaches (Moreno-Flores et al., 2003b; Moreno-
Flores et al., 2003a) aimed to resolve all these problems, including the composition of 
the cultures and the availability of regenerative OECs. We prepared primary cultures 
from human OB-OECs cadaver donors and we reversibly immortalized them (Garcia-
Escudero et al., 2010; Lim et al., 2010). Additionally, we also prepared cultures of 
human OM-cells that retained the capacity for axonal regeneration in a co-culture 
model (Garcia-Escudero et al., 2012). Our final aim was to prepare cell banks with 
batches of biosecure, histocompatible, “de-immortalized” OEC clonal lines. These cells 
would be typed and quantified for axonal regeneration using co-culture models with 
adult CNS neurons (Moreno-Flores and Avila, 2006; Moreno-Flores and Avila, 2010). 
However, the legal and ethical problems of transplantation with genetically modified 
cells, even for cells with modifications that would include extraordinary biosecurity 
measures are not inconsiderable. Nevertheless, this interesting possibility might be 
addressed in the future, trying to ensure the best biosecurity for patients and using 
OECs alone, or in combined treatments with cellular and pharmacological agents. 
 
7  І  CONCLUSIONS AND FUTURE PERSPECTIVES 
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In this review, we have set out the current status of research into OECs and the 
possibility of using these cells to treat SCI: morphological aspects, physiological 
functions, and the factors that they produce and that can be used to restore CNS 
function. Taking into account all the biological characteristics described in this review, 
we conclude that these cells possess a notable ability to stimulate axon 
repair/plasticity and/or to support the sparing of axons in the CNS. 
These studies have revealed that OECs can act as therapeutic agents in several 
different ways. They are able to stimulate angiogenesis, and to modify PNNs and the 
glial scar (producing different proteinases like MMP2 and PAI-1: Fig. 4), especially 
when mixed with reactive astrocytes. In this way they can foster the outgrowth of 
axons to differing degrees, as well as through the production of trophic factors like 
NGF, BDNF and GDNF. Finally, they can also produce new myelination of the 
injured/repaired axons by direct or indirect mechanisms. OECs are a unique type of glia 
found exclusively in the olfactory system and as such, they are relatively accessible in 
rodents and humans. Therefore, they can be extracted for autologous grafting, which 
removes the likelihood of producing an immune rejection response. 
Many laboratories have now used OECs in different acute and chronic experimental 
models of SCI, some of which have produced a surprising degree of functional recovery 
when evaluated with different tests. Finally, several clinical trials have been conducted, 
with promising results. Today, OECs are considered an interesting avenue to explore in 
cell transplantation research in order to restore the integrity and functionality of the 
CNS, specifically in response to SCI and in demyelinating diseases. Hence, OECs appear 
to represent a promising tool that will probably be very fruitful in the near future, 
particularly in combination with other strategies. 
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FIGURE LEGENDS 
 
Figure 1. The neural crest as a source of OECs during development. OEC-precursors originate 
exclusively from the neural crest. During development, these OEC-precursors migrate to the 
olfactory placodes (OP; green) to subsequently form part of the olfactory system. Figures were 
produced using Servier Medical Art. 
Figure 2. A schematic representation of the adult olfactory system. The cellular composition 
and the diverse parts of the olfactory system are shown. GBCs are the main cells that produce 
neurons as they proliferate (auto-renewal) and generate new olfactory neurons, ORN. These 
cells extend an apical dendrite and a basal axon across the LP, to reach their targets in the 
olfactory glomeruli situated in the CNS. There, they establish connections with mitral and 
tufted cells that send information through the olfactory tract to the olfactory cortex. HBCs are 
usually inactive but when severe injury occurs, they can self-renew and generate most of the 
olfactory cells needed to restock the olfactory epithelium. HBCs may also be able to generate 
new OECs. Abbreviations: CNS (Central Nervous System), PNS (Peripheral Nervous System), LP 
(Lamina Propria), HBC (Horizontal Basal Cells), GBC (Globose Basal Cells), ORNi (Immature 
Olfactory Receptor Neuron), ORNm (Mature Olfactory Receptor Neuron), OEC (Olfactory 
Ensheathing Cells). Figures were produced using Servier Medical Art.  
Figure 3. OECs express different specific markers. A. OECs have different antigenic phenotypes 
depending on their location in the CNS or PNS. Generally, OECs express vimentin, S100β and 
GFAP, although they also can express p75NTR, E-NCAM or NPY depending on the region of the 
CNS or PNS where they are situated. B. In vitro, OECs can be segregated into two phenotypic 
subpopulations: i) Schwann cell-like, characterized by a spindle shape and strong p75NTR 
expression; ii) and astrocyte-like, with a similar morphology to flattened astrocytes and strong 
E-NCAM expression. GFAP immunostaining in culture has been defined as fibrous for 
astrocyte-like OECs (Franceschini and Barnett, 1996), yet in our experience (Moreno-Flores et 
al., 2003b) this staining is always diffuse in OECs, corresponding to weak GFAP expression (in 
western blots) relative to cultured astrocytes. Abbreviations: CNS (Central Nervous System), 
GFAP (Glial Fibrillary Acidic Protein), NCAM (Neural Cell Adhesion Molecule), NPY 
(Neuropeptide Y), PNS (Peripheral Nervous System), LP (Lamina Propria), ONL (Olfactory Nerve 
Layer), OECs (Olfactory Ensheathing Cells). Figures were produced using Servier Medical Art. 
Figure 4. Interactions between OECs and neurons implicated in neuroregeneration. Under 
physiological conditions OECs and neurons are in permanent communication through the 
interaction of adhesion molecules, diffusible neurotrophic factors, proteases and cytokines. 
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Inhibitory factors, both ligands and receptors, can establish axon pathways and/or hinder OEC 
migration. Abbreviations: CSPG (Chondroitin sulphate proteoglycans), OECs (Olfactory 
Ensheathing Cells), PNN (Perineuronal Net). Figures were produced using Servier Medical Art. 
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Figure 1. The neural crest as a source of OECs during development. OEC-precursors originate exclusively 
from the neural crest. During development, these OEC-precursors migrate to the olfactory placodes (OP; 
green) to subsequently form part of the olfactory system. Figures were produced using Servier Medical Art.  
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Figure 2. A schematic representation of the adult olfactory system. The cellular composition and the diverse 
parts of the olfactory system are shown. GBCs are the main cells that produce neurons as they proliferate 
(auto-renewal) and generate new olfactory neurons, ORN. These cells extend an apical dendrite and a basal 
axon across the LP, to reach their targets in the olfactory glomeruli situated in the CNS. There, they 
establish connections with mitral and tufted cells that send information through the olfactory tract to the 
olfactory cortex. HBCs are usually inactive but when severe injury occurs, they can self-renew and generate 
most of the olfactory cells needed to restock the olfactory epithelium. HBCs may also be able to generate 
new OECs. Abbreviations: CNS (Central Nervous System), PNS (Peripheral Nervous System), LP (Lamina 
Propria), HBC (Horizontal Basal Cells), GBC (Globose Basal Cells), ORNi (Immature Olfactory Receptor 
Neuron), ORNm (Mature Olfactory Receptor Neuron), OEC (Olfactory Ensheathing Cells). Figures were 
produced using Servier Medical Art.  
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Figure 3. OECs express different specific markers. A. OECs have different antigenic phenotypes depending 
on their location in the CNS or PNS. Generally, OECs express vimentin, S100β and GFAP, although they also 
can express p75NTR, E-NCAM or NPY depending on the region of the CNS or PNS where they are situated. 
B. In vitro, OECs can be segregated into two phenotypic subpopulations: i) Schwann cell-like, characterized 
by a spindle shape and strong p75NTR expression; ii) and astrocyte-like, with a similar morphology to 
flattened astrocytes and strong E-NCAM expression. GFAP immunostaining in culture has been defined as 
fibrous for astrocyte-like OECs (Franceschini and Barnett, 1996), yet in our experience (Moreno-Flores et al., 
2003b) this staining is always diffuse in OECs, corresponding to weak GFAP expression (in western blots) 
relative to cultured astrocytes. Abbreviations: CNS (Central Nervous System), GFAP (Glial Fibrillary Acidic 
Protein), NCAM (Neural Cell Adhesion Molecule), NPY (Neuropeptide Y), PNS (Peripheral Nervous System), 
LP (Lamina Propria), ONL (Olfactory Nerve Layer), OECs (Olfactory Ensheathing Cells). Figures were 
produced using Servier Medical Art.  
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Figure 4. Interactions between OECs and neurons implicated in neuroregeneration. Under physiological 
conditions OECs and neurons are in permanent communication through the interaction of adhesion 
molecules, diffusible neurotrophic factors, proteases and cytokines. Inhibitory factors, both ligands and 
receptors, can establish axon pathways and/or hinder OEC migration. Abbreviations: CSPG (Chondroitin 
sulphate proteoglycans), OECs (Olfactory Ensheathing Cells), PNN (Perineuronal Net). Figures were 
produced using Servier Medical Art.  
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 TABLE 1. Factors expressed by OECs 
 A) Expression  of Pro-Regenerative Factors 
 Factors References Receptors References 
N
e
u
ro
tr
o
p
h
ic
 f
a
ct
o
rs
 /
 C
y
to
k
in
e
s 
/ 
P
ro
te
a
se
s 
Neuregulins (NRG) 
 
Nerve Growth Factor (NGF) 
Brain Derived Neuro-trophic 
Factor (BDNF) 
 
Glial cell line-derived 
neurotrophic factor (GDNF) 
 
Neurturin (NTN) 
 
Neurotrophin (NT)-4 
Ciliary Neurotrophic Factor 
(CNTF)  
 
 
Boruch et al., 2001  
 
Lipson et al., 2003 
 
Moreno-Flores et al., 2002  
 
Pastrana et al., 2007  
 
Woodhall et al., 2001 
ErbB2-4 
 
P75NTR 
TrkB 
TrkC 
 
 
GFRα-1 
 
GFRα-2 
  
  
 
Franceschini & Barnett 
1996 
 
Lipson et al., 2003 
 
Moreno-Flores et al., 
2003a&b 
Pollock et al., 1999 
 
Ramón-Cueto&Nieto-
Sampedro, 1992 
 
Woodhall et al., 2001 
S100β 
Franceschini and Barnett, 
1996 
Lipson et al., 2003 
Moreno-Flores et al., 
2003a&b 
Pastrana et al., 2006 
Lim et al., 2010 
Vincent et al., 2005 
- - 
Interleukin-6  
(bulbectomy) 
 
 
CX3CL1/Fractalkine 
 
Other Cytokines (TGFβ3) 
Nan et al., 2001 
 
 
 
Ruitenberg et al., 2008 
 
Pastrana et al., 2006 
 
IL-6R and LIFR 
(bulbectomy) 
 
- 
Nan et al., 2001; 
 
 
 
- 
Other cytokine receptors 
(TNFR and IL1RL1) 
Pastrana et al., 2006 
Roet and Verhaagen, 
2014 
Matrix Metalloproteases:  
Pastrana et al., 2006 
- - 
MMP2 and MMP9 
Serpine-1 Simon et al., 2011 - - 
A
d
h
e
si
o
n
 M
o
le
cu
le
s L1 
Doucette, 1996  
Franceschini and Barnett, 
1996 
Kafitz and Greer, 1998 
Moreno-Flores et al., 2003a 
- - 
E-NCAM 
Laminin 
Fibronectin 
Type IV collagen 
Amyloid Precursor Protein 
(APP) 
 
 
 B) Expression of Inhibitory Factors 
 Factors References Receptors/Others References 
M
ig
ra
ti
o
n
 
Nogo 
 
Myelin 
 
Chondroitin Sulphate 
Proteoglycan (CSPG) 
Nocentini et al., 2012 
Reginensi et al., 2015 
Su et al., 2007 
NgR 
 
Nocentini et al., 2012 
Su et al., 2007 
Woodhall et al., 2003 
  
- - TIMP2 Pastrana et al., 2006 
Ephrin A1 Pastrana et al., 2006 - - 
Slit-2 (migration inhibitor for 
OEG) 
Huang et al., 2011 
Wang and Huang, 2012 
Robo receptors 
Huang et al., 2011 
Wang and Huang, 2012 
Fibulin-3  Vukovic et al., 2009b   
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TABLE 2. Factors secreted by OECs 
Pro-regenerative Factors Inhibitory Factors 
Factors References Factors References 
D
if
fu
si
b
le
 F
a
ct
o
rs
 
Neuregulins (NRG) 
 
Boruch et al., 2001 
 
 
Semaphorin 3A  
 
 
Schwarting et al., 2000 
Nerve Growth Factor 
(NGF) 
Brain Derived 
Neurotrophic Factor 
(BDNF) 
Pastrana et al., 2007; 
 
Woodhall et al., 2001 
 
MMP2 y MMP9 Pastrana et al., 2006   
Serpine-1 Simon et al., 2011   
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TABLE 3: OEC transplantation and combined treatments in animal models of SCI 
Study Level/Type of Lesion Transplantation Axonal tracing/staining Electrophysiology Functional Recovery  
Andrews & Stelzner 2007 DCC at T8-9 (rat) 
OECs or SchCs from adult 
transgenic rats expressing 
alkaline phosphatase (AP). 
Acute and delayed (2 
weeks) allogenic 
transplantation in SCI 
(immunosuppression with 
cyclosporine A). 
Survival: 2 hr, 2 days, and 2 
or 4 weeks 
Immunostaining: CGRP, 
GAP43 and neurofilament 
- - 
Chuah et al., 2004 
DC Transection T8-9 
(Rat) 
P3 pooled rat OB & mucosa 
OECs, encapsulated or 
injected. Experiment with 
Hoechst labelled and acute 
injury. 
Survival: 5 weeks 
Tracing: CST anterograde 
Fluororuby 
- - 
Collazos-Castro et al, 2005 
Mild C7 contusion 
(complete disruption 
of dorsal CST) 
Adult OECs for acute SCI. 
Survival: 3.5 months 
CST anterograde tracing 
Neurofilament staining 
- 
Kinematics of locomotion 
with video recording (no 
improvement with the 
transplants) 
De Lucia et al., 2006 
DL hemisection T8 in 
rats 
OECs line (T-SV40 
immortalized) 
Survival: 10, 14 days and 21 
weeks 
Thionin staining - Grid Walking 
Fouad et al., 2005 
Complete T8 
transection 
Adult rat SC-matrigel + 
rostrocaudal adult rat OECs 
+ chondroitinase vs. graft 
only and untreated 
Survival: 2 and 12 weeks 
Tracing: Reticulospinal tract 
with Micro Ruby (dextran, 
tetramethylrhodamine, and 
biotin); CST with BDA 
Staining: serotoninergic axons 
(5-HT
+
) 
 
Myelinated axons 
- 
- Open field locomotion: 
BBB scale. 
-Sensory test using von 
Frey hairs 
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Fouad et al., 2009 
Complete T8 
transection 
Adult rat SC-matrigel + 
rostrocaudal adult rat OECs 
+ chondroitinase vs. graft 
only and untreated. 
Survival: 14 weeks 
Staining: serotoninergic axons 
(5-HT
+
) 
Bladder wall staining: α-
smooth muscle actin and 
collagen III deposition 
- - Bladder function 
Garcia-Alias 2004 
Photochemical injury 
of rats at the T8 level 
(Rose Bengal + 
halogen 80 kLux, 2.5 
min.) 
Rat OECs or SchCs for acute 
SCI 
Survival: 3 months 
Tracing: anterograde for CST 
(DiI crystals in sensory motor 
cortex) assessed at T13. 
 
Staining: serotoninergic axons 
(5-HT
+
: no differences 
between the groups for this 
staining). 
Motor 
evoked potentials (MEPs), 
somatosensory evoked 
potentials (SSEPs) and  
compound muscle action 
potentials (no differences 
between the groups for 
these latter potentials). 
- Open field locomotion: 
BBB scale. 
-Test of inclined plane 
(maximum angle). 
-Plantar algesimetry test 
 
Gorrie et al., 2010 
Moderate T10 
contusion of athymic 
rats. 
Adult human LP-OECs GFP 
labelled; 
xenotransplantation in sub-
acute SCI (1 week after 
lesion) 
Survival: 6 weeks (5 weeks 
after transplantation). 
Staining neurofilament 
(NF200) 
- 
- Open field locomotion: 
BBB scale. 
- horizontal ladder rung 
walking test 
 
Ibrahim et al., 2009 
Rhizotomy: C6-T1 
sectioning at dorsal 
roots 
 
Adult rat OECs in 
endogenous matrix with 
GFP transduced cells. 
Survival: 6-8 weeks 
Tracing: BDA injected in DRGs, 
tracing sensory axons and 
ascending projections 
Stimulation of median nerve 
evoked potentials 
monitored on the SC 
dorsum and on the left 
medullary dorsum above 
the cuneate nucleus  
 
Grid climbing (1m grid at 
15º inclination to the 
vertical: Forepaw 
function) 
Some animals respond 
(correlation with 
electrophysiology) 
Ibrahim et al., 2014 
Rhizotomy: C6-T1 
sectioning at dorsal 
roots 
Adult rat mucosa OECs in 
endogenous matrix. Cells 
GFP transduced 
Survival: 8 weeks 
Staining: Neurofilament - 
Grid climbing (Forepaw 
function) did not improve 
Page 97 of 102
John Wiley & Sons, Inc.
GLIA
Imaizumi et al., 2000a T11 DC transection  
Transgenic Pig OECs 
CFDA, SE loaded 
Survival: 4-5 weeks 
Ultrastructural analysis of 
myelinated axons (MET). 
Field potentials, recording of 
the propagated action 
potentials (amplitude and 
conduction velocity) 
 
- 
Imaizumi et al., 2000b T11 DC transection  
Neonatal OECs or Adult 
SchCs CFDA, SE loaded 
Survival: 5-6 weeks 
DR axons BD traced/ 
Ultrastructural analysis of 
myelinated axons (MET) 
 
Field potentials, recording of 
the propagated action 
potentials (amplitude and 
conduction velocity) 
- 
Lee et al., 2004 T8 Transection 
Adult rat OECs in acute SCI. 
Marked with 
superparamagnetic iron 
oxide nanoparticles for MRI 
detection 
Neurofilament staining - 
- Open field locomotion: 
BBB scale 
(no improvement) 
Li et al., 1997 
CST stereotaxic 
electrolytic C1-2 
lesion 
Adult OECs in acute SCI (p75 
immunolabelling) 
Survival: 6, 10 days, 3, 4 & 9 
weeks 
CST BD anterograde tracing/ 
Ultrastructural analysis of 
myelinated axons (MET) 
 
- - 
Li et al., 1998 
CST stereotaxic 
electrolytic C1-2 
lesion  
Adult OECs in acute SCI 
(p75/fibronectin/GFAP/ 
L1/Laminin/GFAP 
immunolabelling 
identification) 
Survival: 1-14 days, 3, 4, 6 
weeks, 3 months 
CST BD anterograde tracing/ 
P0 staining and ultrastructural 
analysis of myelinated axons 
(MET) 
 
- - 
Li et al., 2003 
Upper cervical 
hemisection. 
Adult OECs-matrix GFP 
labelled in acute SCI. 
Survival: 3, 10 days and 2 
months transplantation 
Staining: Neurofilament and 
Thionin neurons at T8 
Electrophysiological 
recording of the rhythmic 
compound action potentials 
from phrenic nerves 
(respiratory rhythm) 
 
- Climbing test 
Li et al., 2011 
T10 Contusion 
 
Adult OECs from OB of GFP 
transgenic rats (OBOECs-
GFP). 
In subacute (7 days) SCI 
Survival: 1-6 weeks after. 
Tracing: choleragenoid B 
subunit-conjugated 
horseradish peroxidase (CTB-
HRP) injected at L3. 
Examination of marked  
Corticospinal 
somatosensory evoked 
potential recording and 
analysis. 
- Open field locomotion: 
BBB scale. 
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 Lopez-Vales et al., 2004 
Photochemical injury 
at the T8 level (Rose 
Bengal + halogen 200 
kLux, 2.5 min.) 
Adult rat OECs for acute SCI. 
Survival: 3, 7 and 14 days 
No staining or tracing for 
axonal tracts. 
Immunostaining for COX-2, 
VEGF, GFAP and lectin 
Motor and Somatosensory 
evoked potentials 
- Open field locomotion: 
BBB scale. 
- Pain sensibility 
Lopez-Vales et al., 2006 
Complete T8 
transection 
Young rat OECs (P22-23) in 
acute and subacute (1 
week) SCIs. 
Survival: 9.5 months 
BDA anterograde tracing of 
CST 
 
Immunostaining: 
NF-200, GAP43, CGRP. 
Serotonin (5-HT
+
) raphespinal 
tract and noradrenergic 
(DβOH
+
) coeruleospinal tract. 
Motor evoked potentials 
(MEPs) and compound 
muscle action potentials 
(lumbar spinal reflexes: 
sciatic nerve/plantar 
muscles). 
- Open field locomotion: 
BBB scale. 
- Climbing test 
Lopez-Vales et al., 2007 
Complete T8 
transection 
Young rat OECs (P22-23) in 
chronic (45 days after 
injury) SCI. 
Survival: 5 months after 
transplantation (6.5 months 
after injury). 
BDA anterograde tracing of 
CST 
 
Immunostaining: 
Serotonin (5-HT+) raphespinal 
tract. 
 
Motor evoked potentials 
(MEPs) and compound 
muscle action potentials 
(lumbar spinal reflexes: 
sciatic nerve/plantar 
muscles). 
- Open field locomotion: 
BBB scale. 
 
Lu et al., 2001 T10 Transection (Rat) 
Adult rat olfactory LP-OECs 
or pieces of olfactory LP (vs. 
respiratory LP) transplanted 
in acute SCI 
OECs labelled with cell 
tracker green 
Survival: 8-10 weeks after 
transplantation + 2-4 days 
post-tracing. 
Tracing with fluororuby 
injected into the SC at T11. 
Retrograde labelling of axons 
crossing the transplantation 
site 
Staining: Neurofilament, 
Serotonin (5-HT) positive 
axons (raphespinal tract). 
 
Physiological assessment of 
reflexes (H-reflex repetitive 
stimulation at 10 Hz) 
- Open field locomotion: 
BBB scale. 
 
Lu et al., 2002 
T10 Transection (Rat) 
4 weeks after 
removal of the scar 
tissue and 
transplantation 
OECs in chronic SCI 
(transplantation: 4 weeks 
delayed) 
Survival: 10 weeks after 
transplantation (14 weeks 
after injury) 
Tracing: Retrograde FG 
injected at T12 and evaluated 
in Raphe neurons 
Staining: serotonin
+
 axons 
(raphespinal tract) 
Serotonine 
- 
- Open field locomotion: 
BBB scale. 
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Moreno-Flores et al., 
2006/Pastrana et al., 2006 
DC C3 Crush  
Adult BrdU labelled –OECs 
(immortalized TEG3 line) for 
acute injury + 
PGDH immunostaining 
Survival: 1,2, 4 and 8 weeks 
survival 
CST: BDA anterograde tracing 
and sensory ascending 
projections (Fasciculus 
Gracilis): CTB transganglionar 
tracing 
- 
- Beam walking. 
 
- Tape removal. 
Pearse et al., 2007 
Moderate T9 
contusion  
Adult OECs or SchCs eGFP 
transduced or Y 
chromosome labelled for 
subacute (1 week) injury, 
alone and in combination. 
Survival:3 days and 3, 9 
weeks 
CST: BDA anterograde tracing 
and sensory ascending 
projections (Fasciculus  
Gracilis): CTB transganglionar 
tracing 
Staining CGRP & 5HT 
- 
- Open field locomotion: 
BBB scale. 
- Conditioned locomotion 
foot print. 
- Grid Walk. 
Plant et al., 2003 
Moderate T9-10 
contusion 
Adult OECs in acute and 
subacute (7 days) SCI 
Survival: 2 months 
Retrograde FG tracing. 
Reticular F., Raphe, Vestibular 
and Red nuclei. 
Immunostaining: Serotonin, 
CGRP, Neurofilament (RT97) & 
GAP43 
- 
- Open field locomotion: 
BBB scale. 
 
Ramer et al., 2004 DL C4 funiculus crush 
Mucosa OECs from  
postnatal (P5-P7) transgenic 
eGFP mice. 
Xenotransplantation in rat 
(cyclosporine 
immunosuppresion). 
Survival: 2 7, 28 & 60 days 
BDA anterograde tracing of 
rubrospinal axons. 
Staining: βIII tubulin, NF-200, 
serotonin, TH, CGRP. 
 
Staining: RECA (angiogenesis) 
GFAP and rat-p75 
- - 
Ramón-Cueto & Nieto-
Sampedro 1994 
Rhizotomy - one 
dorsal root at T10 
Adult Hoechst labelled-OECs 
in acute injury 
Survival: 3 weeks 
Dil dorsal root axonal tracing 
Staining: CGRP & GAP43 
- - 
Ramón-Cueto et al., 1998 
Complete T9 
transection 
Adult cells in acute injury: 
SC in PVC/matrigel + 
Hoechst labelled OECs 
(rostral and caudal stumps). 
Survival: 6 weeks 
WGA-HRP anterograde and 
retrograde axonal tracing 
injected at C7. 
Staining: neurofilament CGRP 
and Serotonin 
 
- - 
Ramón-Cueto et al., 2000 T8 Transection 
Adult OECs, Hoechst 
labelled in acute injury. 
CST tracing: BDA anterograde 
Staining: Serotonin 
- 
- Climbing onto a vertical 
grid. 
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Survival: 7 months (raphespinal fibers) & 
Dopamine β hydroxylase 
(Noradrenergic coeruleospinal 
fibres) 
 
- Contact placing and 
propioceptive responses 
Richter et al., 2005 
DL C3-4 funiculus 
crush 
LP or OB-OECs from  
postnatal (P5) transgenic 
eGFP mice. 
Xenotransplantation in rat 
(cyclosporine 
immunosuppresion). 
Survival: 24 hr, 28 days 
Staining: Substance P, CGRP 
(Dorsal root afferents), 5-HT 
(Raphespinal), TH (CA fibres) 
 
Staining: Rat-RECA 
(angiogenesis) 
GFAP and rat-p75 
- 
- Autotomy: decreased 
for OB-OECs vs. LP-OECs 
Ruitenberg et al., 2003 
Unilateral C4 DL 
Funiculus 
Transection 
Adult rat OECs AdV 
transduced with NT-3 
and/or BDNF, or LacZ vs 
uninfected OECs. 
AdV lacZ transduced OECs. 
Survival: 4 months 
BDA anterograde tracing of 
the rubrospinal tract. 
 
Immunostaining for 
Neurofilament 
Rubrospinal MEPs 
- Open field locomotion: 
BBB scale. 
- Horizontal rope walking 
Ruitenberg et al., 2005 
Complete C4 
transection of the 
right dorsal 
hemisphere of the 
Spinal cord 
Adult rat OECs AdV 
transduced with NT-3 vs 
uninfected OECs, 
and lacZ transduced OECs. 
Survival: 4 months 
BDA anterograde tracing of 
CST. 
 
- 
- Open field locomotion: 
BBB scale. 
- Forelimb reaching task 
No changes between 
groups 
Takami et al., 2002 
Moderate T9 spinal 
cord contusion 
Adult rat OECs and/or SC in 
sub-chronic SCI (1 week) 
Survival: 12 weeks 
Anterograde Tracing: CST with 
BDA, 
reticulospinal tract with 
dextran - fluorescein 
and vestibulospinal tract with 
dextran-rhodamine 
Retrograde tracing: Fast Blue 
caudal to lesion site (T10-11), 
Staining: Neurofilament, 
CGRP, 5-HT (serotoninergic) 
 
- 
- Open field locomotion: 
BBB scale. 
 
Toft et al., 2007 L3/4 DC transection 
P7 and adult rat OECs- 
(eGFP transduced to follow 
the cells in some animals) 
Survival: 0.5, 2-3 Months 
DRG BDA tracing and CTB L4 
and L5 spinal nerves tracing 
Cord dorsum potentials and 
sensory evoked potentials 
- 
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BBB: Basso–Beattie–Bresnahan locomotor rating scale 
BD/BDA: Biotinylated dextran amine. 
CA: Catecholamine. 
CFDA, SE: 5-(and -6)-carboxyfluoresceine diacetate, succinimidyl ester 
CST: Corticospinal tract 
CTB: Cholera Toxin subunit B 
DβOH: Dopamine-β-Hydroxylase 
DC: Dorsal column, DCC: Dorsal column crush 
Dil: Fluorescent carbocyanine Dil dye 
DL: Dorsolateral 
DR: Dorsal root 
FG: FluoroGold 
 
 
Hoechst: fluorochrome bisbenzimide (Hoechst 33342) 
LP: Lamina propria 
MEPs: motor evoked potentials 
MRI: Magnetic Resonance Imaging 
OB: Olfactory Bulb 
OECs: Olfactory ensheathing glia cells from OB (LP-OECs only when indicated) 
PGDH: 3-phosphoglycerate dehydrogenase 
SchC: Schwann cells 
SSEPs: somatosensory evoked potentials 
TH: Tyrosine Hydroxylase 
WGA-HRP: wheat germ agglutinin–horseradish peroxidase 
 
 
 
 
Vavrek et al., 2007 
Complete 
transection at T8 
level 
Adult rat SC-matrigel + 
rostrocaudal adult rat OECs 
+ chondroitinase vs. only 
graft and not treated 
Survival: 2 and 12 weeks 
Retrograde tracing with FG 
injected caudal to the lesion 
site 
- - 
Wang et al., 2010 
Right lateral 3/4 
spinal cord T9 
transection 
Fetal (E13-14) cortical rat 
NSCs and/or Adult rat OECs 
transplanted for sub-chronic 
SCI (1 week) 
Survival: 12 weeks 
Staining: Neurofilament (NF-
200) 
- 
- Open field locomotion: 
BBB scale. 
 
Yamamoto et al., 2009 
CST stereotaxic C1-2 
electrolytic lesion 
Adult mucosal OECs GFP 
labelled in chronic SCI (8 
weeks) 
Survival: 10 weeks after 
transplantation (18 weeks 
after initial surgery) 
CST BD anterograde tracing - 
-  Fore-paw function: 
Directed fore-paw 
reaching 
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